

Silvio Danese

List of Publications by Citations

Source: <https://exaly.com/author-pdf/1120660/silvio-danese-publications-by-citations.pdf>
Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

595 papers	27,004 citations	77 h-index	149 g-index
748 ext. papers	35,054 ext. citations	6.6 avg, IF	7.5 L-index

#	Paper	IF	Citations
595	Vedolizumab as induction and maintenance therapy for ulcerative colitis. <i>New England Journal of Medicine</i> , 2013 , 369, 699-710	59.2	1465
594	The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management. <i>Journal of Crohn's and Colitis</i> , 2010 , 4, 28-62	1.5	1071
593	Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target. <i>American Journal of Gastroenterology</i> , 2015 , 110, 1324-38	0.7	1024
592	Ulcerative colitis. <i>New England Journal of Medicine</i> , 2011 , 365, 1713-25	59.2	785
591	Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis. <i>New England Journal of Medicine</i> , 2017 , 376, 1723-1736	59.2	771
590	Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. <i>Gastroenterology</i> , 2014 , 146, 392-400.e3	13.3	593
589	Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn's disease: a phase 3 randomised, double-blind controlled trial. <i>Lancet, The</i> , 2016 , 388, 1281-90	40	539
588	The safety of vedolizumab for ulcerative colitis and Crohn's disease. <i>Gut</i> , 2017 , 66, 839-851	19.2	478
587	Imaging techniques for assessment of inflammatory bowel disease: joint ECCO and ESGAR evidence-based consensus guidelines. <i>Journal of Crohn's and Colitis</i> , 2013 , 7, 556-85	1.5	438
586	Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease. <i>Gut</i> , 2011 , 60, 463-72	19.2	426
585	Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial. <i>Lancet, The</i> , 2017 , 390, 2779-2789	40	403
584	Development of the Crohn's disease digestive damage score, the Lhann score. <i>Inflammatory Bowel Diseases</i> , 2011 , 17, 1415-22	4.5	395
583	3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn's Disease 2016: Part 2: Surgical Management and Special Situations. <i>Journal of Crohn's and Colitis</i> , 2017 , 11, 135-149	1.5	387
582	Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 3: special situations. <i>Journal of Crohn's and Colitis</i> , 2013 , 7, 1-33	1.5	361
581	Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis. <i>New England Journal of Medicine</i> , 2019 , 381, 1201-1214	59.2	354
580	Angiogenesis as a novel component of inflammatory bowel disease pathogenesis. <i>Gastroenterology</i> , 2006 , 130, 2060-73	13.3	308
579	Diarrhea During COVID-19 Infection: Pathogenesis, Epidemiology, Prevention, and Management. <i>Clinical Gastroenterology and Hepatology</i> , 2020 , 18, 1663-1672	6.9	285

578	European consensus on the diagnosis and management of iron deficiency and anaemia in inflammatory bowel diseases. <i>Journal of Crohn's and Colitis</i> , 2015 , 9, 211-22	1.5	278
577	Inflammation and coagulation in inflammatory bowel disease: The clot thickens. <i>American Journal of Gastroenterology</i> , 2007 , 102, 174-86	0.7	267
576	Advanced age is an independent risk factor for severe infections and mortality in patients given anti-tumor necrosis factor therapy for inflammatory bowel disease. <i>Clinical Gastroenterology and Hepatology</i> , 2011 , 9, 30-5	6.9	253
575	Results from the 2nd Scientific Workshop of the ECCO. I: Impact of mucosal healing on the course of inflammatory bowel disease. <i>Journal of Crohn's and Colitis</i> , 2011 , 5, 477-83	1.5	247
574	Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis. <i>New England Journal of Medicine</i> , 2019 , 381, 1215-1226	59.2	240
573	New therapies for inflammatory bowel disease: from the bench to the bedside. <i>Gut</i> , 2012 , 61, 918-32	19.2	234
572	Long-term Efficacy and Safety of Stem Cell Therapy (Cx601) for Complex Perianal Fistulas in Patients With Crohn's Disease. <i>Gastroenterology</i> , 2018 , 154, 1334-1342.e4	13.3	220
571	Biologic Therapies and Risk of Infection and Malignancy in Patients With Inflammatory Bowel Disease: A Systematic Review and Network Meta-analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2016 , 14, 1385-1397.e10	6.9	219
570	Defining Disease Severity in Inflammatory Bowel Diseases: Current and Future Directions. <i>Clinical Gastroenterology and Hepatology</i> , 2016 , 14, 348-354.e17	6.9	217
569	Outcomes of COVID-19 in 79 patients with IBD in Italy: an IG-IBD study. <i>Gut</i> , 2020 , 69, 1213-1217	19.2	208
568	Development of the Lhann index to assess digestive tract damage in patients with Crohn's disease. <i>Gastroenterology</i> , 2015 , 148, 52-63.e3	13.3	198
567	Development and validation of the Nancy histological index for UC. <i>Gut</i> , 2017 , 66, 43-49	19.2	196
566	Biologic agents for IBD: practical insights. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2015 , 12, 537-45	24.2	196
565	STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD. <i>Gastroenterology</i> , 2021 , 160, 1570-1583	13.3	191
564	Genetic factors conferring an increased susceptibility to develop Crohn's disease also influence disease phenotype: results from the IBDchip European Project. <i>Gut</i> , 2013 , 62, 1556-65	19.2	184
563	Ulcerative colitis. <i>Nature Reviews Disease Primers</i> , 2020 , 6, 74	51.1	182
562	Once-daily budesonide MMX in active, mild-to-moderate ulcerative colitis: results from the randomised CORE II study. <i>Gut</i> , 2014 , 63, 433-41	19.2	173
561	Infliximab Reduces Endoscopic, but Not Clinical, Recurrence of Crohn's Disease After Ileocolonic Resection. <i>Gastroenterology</i> , 2016 , 150, 1568-1578	13.3	171

560	Efficacy and Safety of MEDI2070, an Antibody Against Interleukin 23, in Patients With Moderate to Severe Crohn's Disease: A Phase 2a Study. <i>Gastroenterology</i> , 2017 , 153, 77-86.e6	13.3	162
559	Application of Artificial Intelligence to Gastroenterology and Hepatology. <i>Gastroenterology</i> , 2020 , 158, 76-94.e2	13.3	162
558	Biological agents for moderately to severely active ulcerative colitis: a systematic review and network meta-analysis. <i>Annals of Internal Medicine</i> , 2014 , 160, 704-11	8	158
557	Environmental Risk Factors for Inflammatory Bowel Diseases: An Umbrella Review of Meta-analyses. <i>Gastroenterology</i> , 2019 , 157, 647-659.e4	13.3	155
556	ECCO position statement: the use of biosimilar medicines in the treatment of inflammatory bowel disease (IBD). <i>Journal of Crohn's and Colitis</i> , 2013 , 7, 586-9	1.5	149
555	ECCO Position Statement on the Use of Biosimilars for Inflammatory Bowel Disease-An Update. <i>Journal of Crohn's and Colitis</i> , 2017 , 11, 26-34	1.5	148
554	VEGF-C-dependent stimulation of lymphatic function ameliorates experimental inflammatory bowel disease. <i>Journal of Clinical Investigation</i> , 2014 , 124, 3863-78	15.9	144
553	Mesenchymal Stem Cells Reduce Colitis in Mice via Release of TSG6, Independently of Their Localization to the Intestine. <i>Gastroenterology</i> , 2015 , 149, 163-176.e20	13.3	142
552	Crohn's disease. <i>Nature Reviews Disease Primers</i> , 2020 , 6, 22	51.1	131
551	Efficacy of adalimumab in patients with Crohn's disease and symptomatic small bowel stricture: a multicentre, prospective, observational cohort (CREOLE) study. <i>Gut</i> , 2018 , 67, 53-60	19.2	126
550	Validation of endoscopic activity scores in patients with Crohn's disease based on a post hoc analysis of data from SONIC. <i>Gastroenterology</i> , 2013 , 145, 978-986.e5	13.3	124
549	Switching Reference Medicines to Biosimilars: A Systematic Literature Review of Clinical Outcomes. <i>Drugs</i> , 2018 , 78, 463-478	12.1	123
548	Effects of immunosuppression on immune response to pneumococcal vaccine in inflammatory bowel disease: a prospective study. <i>Inflammatory Bowel Diseases</i> , 2012 , 18, 1042-7	4.5	120
547	Anti-MAdCAM antibody (PF-00547659) for ulcerative colitis (TURANDOT): a phase 2, randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , 2017 , 390, 135-144	4.0	119
546	Tralokinumab for moderate-to-severe UC: a randomised, double-blind, placebo-controlled, phase IIa study. <i>Gut</i> , 2015 , 64, 243-9	19.2	113
545	Paradoxical immune-mediated inflammation in inflammatory bowel disease patients receiving anti-TNF- α agents. <i>Autoimmunity Reviews</i> , 2014 , 13, 15-9	13.6	113
544	Efficacy of Vedolizumab Induction and Maintenance Therapy in Patients With Ulcerative Colitis, Regardless of Prior Exposure to Tumor Necrosis Factor Antagonists. <i>Clinical Gastroenterology and Hepatology</i> , 2017 , 15, 229-239.e5	6.9	112
543	Long-term Efficacy of Vedolizumab for Crohn's Disease. <i>Journal of Crohn's and Colitis</i> , 2017 , 11, 412-424	1.5	112

542	Long-term Efficacy of Vedolizumab for Ulcerative Colitis. <i>Journal of Crohn's and Colitis</i> , 2017 , 11, 400-411	11.5	109
541	Comparing histological activity indexes in UC. <i>Gut</i> , 2015 , 64, 1412-8	19.2	103
540	IOIBD technical review on endoscopic indices for Crohn's disease clinical trials. <i>Gut</i> , 2016 , 65, 1447-55	19.2	102
539	Autologous Hematopoietic Stem Cell Transplantation for Refractory Crohn Disease: A Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , 2015 , 314, 2524-34	27.4	102
538	JAK inhibition using tofacitinib for inflammatory bowel disease treatment: a hub for multiple inflammatory cytokines. <i>American Journal of Physiology - Renal Physiology</i> , 2016 , 310, G155-62	5.1	100
537	Exposure-efficacy Relationships for Vedolizumab Induction Therapy in Patients with Ulcerative Colitis or Crohn's Disease. <i>Journal of Crohn's and Colitis</i> , 2017 , 11, 921-929	1.5	99
536	Randomised clinical trial: mesalazine and/or probiotics in maintaining remission of symptomatic uncomplicated diverticular disease--a double-blind, randomised, placebo-controlled study. <i>Alimentary Pharmacology and Therapeutics</i> , 2013 , 38, 741-51	6.1	98
535	The PROSIT-BIO Cohort: A Prospective Observational Study of Patients with Inflammatory Bowel Disease Treated with Infliximab Biosimilar. <i>Inflammatory Bowel Diseases</i> , 2017 , 23, 233-243	4.5	96
534	IBD risk loci are enriched in multigenic regulatory modules encompassing putative causative genes. <i>Nature Communications</i> , 2018 , 9, 2427	17.4	95
533	Identification of serum and tissue micro-RNA expression profiles in different stages of inflammatory bowel disease. <i>Clinical and Experimental Immunology</i> , 2013 , 173, 250-8	6.2	94
532	Review article: Causative factors and the clinical management of patients with Crohn's disease who lose response to anti-TNF- α therapy. <i>Alimentary Pharmacology and Therapeutics</i> , 2011 , 34, 1-10	6.1	94
531	Venous thromboembolic events in the tofacitinib ulcerative colitis clinical development programme. <i>Alimentary Pharmacology and Therapeutics</i> , 2019 , 50, 1068-1076	6.1	92
530	Colorectal cancer in inflammatory bowel disease: results of the 3rd ECCO pathogenesis scientific workshop (I). <i>Journal of Crohn's and Colitis</i> , 2014 , 8, 5-18	1.5	89
529	Neutrophils in ulcerative colitis: a review of selected biomarkers and their potential therapeutic implications. <i>Scandinavian Journal of Gastroenterology</i> , 2017 , 52, 125-135	2.4	87
528	Systematic review with network meta-analysis: comparative assessment of tofacitinib and biological therapies for moderate-to-severe ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2018 , 47, 454-465	6.1	87
527	Early Predictors of Clinical Deterioration in a Cohort of 239 Patients Hospitalized for Covid-19 Infection in Lombardy, Italy. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	86
526	Methotrexate Is Not Superior to Placebo for Inducing Steroid-Free Remission, but Induces Steroid-Free Clinical Remission in a Larger Proportion of Patients With Ulcerative Colitis. <i>Gastroenterology</i> , 2016 , 150, 380-8.e4	13.3	85
525	Safety of Janus Kinase Inhibitors in Patients With Inflammatory Bowel Diseases or Other Immune-mediated Diseases: A Systematic Review and Meta-Analysis. <i>Gastroenterology</i> , 2020 , 158, 1554-1573.e12	13.3	84

524	Endoscopic, Radiologic, and Histologic Healing With Vedolizumab in Patients With Active Crohn's Disease. <i>Gastroenterology</i> , 2019 , 157, 1007-1018.e7	13.3	82
523	Glycosylation of Immunoglobulin G Associates With Clinical Features of Inflammatory Bowel Diseases. <i>Gastroenterology</i> , 2018 , 154, 1320-1333.e10	13.3	82
522	Next generation of small molecules in inflammatory bowel disease. <i>Gut</i> , 2017 , 66, 199-209	19.2	78
521	Vaccination recommendations for the adult immunosuppressed patient: A systematic review and comprehensive field synopsis. <i>Journal of Autoimmunity</i> , 2017 , 80, 10-27	15.5	78
520	Tofacitinib Induction Therapy Reduces Symptoms Within 3 Days for Patients With Ulcerative Colitis. <i>Clinical Gastroenterology and Hepatology</i> , 2019 , 17, 139-147	6.9	78
519	Review article: the pathophysiology and medical management of diverticulosis and diverticular disease of the colon. <i>Alimentary Pharmacology and Therapeutics</i> , 2015 , 42, 664-84	6.1	77
518	Vascular endothelial growth factor C disrupts the endothelial lymphatic barrier to promote colorectal cancer invasion. <i>Gastroenterology</i> , 2015 , 148, 1438-51.e8	13.3	76
517	Management of IBD during the COVID-19 outbreak: resetting clinical priorities. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2020 , 17, 253-255	24.2	76
516	Viewpoint: knowledge and viewpoints on biosimilar monoclonal antibodies among members of the European Crohn's and Colitis Organization. <i>Journal of Crohn's and Colitis</i> , 2014 , 8, 1548-50	1.5	76
515	Development of the Paris definition of early Crohn's disease for disease-modification trials: results of an international expert opinion process. <i>American Journal of Gastroenterology</i> , 2012 , 107, 1770-6	0.7	76
514	Review article: the role of anti-TNF in the management of ulcerative colitis -- past, present and future. <i>Alimentary Pharmacology and Therapeutics</i> , 2013 , 37, 855-66	6.1	76
513	Development of drugs to target interactions between leukocytes and endothelial cells and treatment algorithms for inflammatory bowel diseases. <i>Gastroenterology</i> , 2014 , 147, 981-9	13.3	75
512	Review article: inherited thrombophilia in inflammatory bowel disease. <i>American Journal of Gastroenterology</i> , 2003 , 98, 1247-51	0.7	75
511	Hyperhomocysteinemia and prevalence of polymorphisms of homocysteine metabolism-related enzymes in patients with inflammatory bowel disease. <i>American Journal of Gastroenterology</i> , 2001 , 96, 2677-82	0.7	75
510	Randomised trial and open-label extension study of an anti-interleukin-6 antibody in Crohn's disease (ANDANTE I and II). <i>Gut</i> , 2019 , 68, 40-48	19.2	75
509	Development of an index to define overall disease severity in IBD. <i>Gut</i> , 2018 , 67, 244-254	19.2	73
508	Incidence and Patterns of COVID-19 Among Inflammatory Bowel Disease Patients From the Nancy and Milan Cohorts. <i>Clinical Gastroenterology and Hepatology</i> , 2020 , 18, 2134-2135	6.9	71
507	Changes in Biosimilar Knowledge among European Crohn's Colitis Organization [ECCO] Members: An Updated Survey. <i>Journal of Crohn's and Colitis</i> , 2016 , 10, 1362-1365	1.5	67

506	Novel therapeutic targets for inflammatory bowel disease. <i>Journal of Autoimmunity</i> , 2017 , 85, 103-116	15.5	66
505	Biosimilars in IBD: from theory to practice. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2017 , 14, 22-31	24.2	66
504	Programming of Intestinal Epithelial Differentiation by IL-33 Derived from Pericryptal Fibroblasts in Response to Systemic Infection. <i>Cell Reports</i> , 2016 , 15, 1743-56	10.6	66
503	Efficacy and Safety of Vedolizumab Subcutaneous Formulation in a Randomized Trial of Patients With Ulcerative Colitis. <i>Gastroenterology</i> , 2020 , 158, 562-572.e12	13.3	65
502	Patient Perspectives on Biosimilars: A Survey by the European Federation of Crohn's and Ulcerative Colitis Associations. <i>Journal of Crohn's and Colitis</i> , 2017 , 11, 128-133	1.5	64
501	Endoscopy in inflammatory bowel diseases during the COVID-19 pandemic and post-pandemic period. <i>The Lancet Gastroenterology and Hepatology</i> , 2020 , 5, 598-606	18.8	63
500	Loss of Response to Vedolizumab and Ability of Dose Intensification to Restore Response in Patients With Crohn's Disease or Ulcerative Colitis: A Systematic Review and Meta-analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2019 , 17, 838-846.e2	6.9	62
499	Early intervention in Crohn's disease: towards disease modification trials. <i>Gut</i> , 2017 , 66, 2179-2187	19.2	60
498	The use of biosimilars in immune-mediated disease: A joint Italian Society of Rheumatology (SIR), Italian Society of Dermatology (SDeMaST), and Italian Group of Inflammatory Bowel Disease (IG-IBD) position paper. <i>Autoimmunity Reviews</i> , 2014 , 13, 751-5	13.6	59
497	Big data in IBD: a look into the future. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2019 , 16, 312-321	14.2	58
496	Adalimumab in active ulcerative colitis: a "real-life" observational study. <i>Digestive and Liver Disease</i> , 2013 , 45, 738-43	3.3	57
495	Infliximab in steroid-dependent ulcerative colitis: effectiveness and predictors of clinical and endoscopic remission. <i>Inflammatory Bowel Diseases</i> , 2013 , 19, 1065-72	4.5	56
494	JAK inhibition in inflammatory bowel disease. <i>Expert Review of Clinical Immunology</i> , 2017 , 13, 693-703	5.1	55
493	JAK selectivity for inflammatory bowel disease treatment: does it clinically matter?. <i>Gut</i> , 2019 , 68, 1893-1899	19.2	55
492	Inflammatory Bowel Disease Care in the COVID-19 Pandemic Era: The Humanitas, Milan, Experience. <i>Journal of Crohn's and Colitis</i> , 2020 , 14, 1330-1333	1.5	55
491	The Expanding Therapeutic Armamentarium for Inflammatory Bowel Disease: How to Choose the Right Drug[s] for Our Patients?. <i>Journal of Crohn's and Colitis</i> , 2018 , 12, 105-119	1.5	55
490	Systematic review with meta-analysis: use of 5-aminosalicylates and risk of colorectal neoplasia in patients with inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2017 , 45, 1179-1192	6.1	54
489	Deep Remission at 1 Year Prevents Progression of Early Crohn's Disease. <i>Gastroenterology</i> , 2020 , 159, 139-147	13.3	54

488	Induction of clinical and colonoscopic remission of mild-to-moderate ulcerative colitis with budesonide MMX 9 mg: pooled analysis of two phase 3 studies. <i>Alimentary Pharmacology and Therapeutics</i> , 2015 , 41, 409-18	6.1	52
487	Bowel Damage as Assessed by the Lhann Index is Reversible on Anti-TNF Therapy for Crohn's Disease. <i>Journal of Crohn's and Colitis</i> , 2015 , 9, 633-9	1.5	52
486	Risk factors for complications after ileocolonic resection for Crohn's disease with a major focus on the impact of preoperative immunosuppressive and biologic therapy: A retrospective international multicentre study. <i>United European Gastroenterology Journal</i> , 2016 , 4, 784-793	5.3	52
485	Intestinal myofibroblast-specific Tpl2-Cox-2-PGE2 pathway links innate sensing to epithelial homeostasis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014 , 111, E4658-67	11.5	52
484	Inflammatory Bowel Disease Management During the COVID-19 Outbreak: The Ten Do's and Don'ts from the ECCO-COVID Taskforce. <i>Journal of Crohn's and Colitis</i> , 2020 , 14, S798-S806	1.5	51
483	Intravenous Versus Oral Iron for the Treatment of Anemia in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. <i>Medicine (United States)</i> , 2016 , 95, e2308	1.8	51
482	The nocebo effect: a clinical challenge in the era of biosimilars. <i>Expert Review of Clinical Immunology</i> , 2018 , 14, 739-749	5.1	49
481	Systematic review with network meta-analysis: comparative efficacy and safety of budesonide and mesalazine (mesalamine) for Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2015 , 41, 1055-65	6.1	49
480	New therapeutic avenues in ulcerative colitis: thinking out of the box. <i>Gut</i> , 2013 , 62, 1642-52	19.2	48
479	Efficacy of Vedolizumab in Fistulising Crohn's Disease: Exploratory Analyses of Data from GEMINI 2. <i>Journal of Crohn's and Colitis</i> , 2018 , 12, 621-626	1.5	47
478	Development of Red Flags Index for Early Referral of Adults with Symptoms and Signs Suggestive of Crohn's Disease: An IOIBD Initiative. <i>Journal of Crohn's and Colitis</i> , 2015 , 9, 601-6	1.5	47
477	Short-term outcomes of laparoscopy combined with enhanced recovery pathway after ileocecal resection for Crohn's disease: a case-matched analysis. <i>Journal of Gastrointestinal Surgery</i> , 2013 , 17, 126-32; discussion p.132	3.3	46
476	First-line therapy in adult Crohn's disease: who should receive anti-TNF agents?. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2013 , 10, 345-51	24.2	46
475	Janus kinase inhibitors for the treatment of inflammatory bowel diseases: developments from phase I and phase II clinical trials. <i>Expert Opinion on Investigational Drugs</i> , 2018 , 27, 595-599	5.9	46
474	Surgical rates in the era of biological therapy: up, down or unchanged?. <i>Current Opinion in Gastroenterology</i> , 2017 , 33, 246-253	3	45
473	Review article: integrating budesonide-MMX into treatment algorithms for mild-to-moderate ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2014 , 39, 1095-103	6.1	45
472	Review article: optimal preparation for surgery in Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2014 , 40, 1009-22	6.1	45
471	Long-term combination therapy with infliximab plus azathioprine predicts sustained steroid-free clinical benefit in steroid-dependent ulcerative colitis. <i>Inflammatory Bowel Diseases</i> , 2014 , 20, 1368-74	4.5	45

470	Anti-IL-6 treatment for inflammatory bowel diseases: next cytokine, next target. <i>Current Drug Targets</i> , 2013 , 14, 1508-21	3	45
469	Intestinal Host Response to SARS-CoV-2 Infection and COVID-19 Outcomes in Patients With Gastrointestinal Symptoms. <i>Gastroenterology</i> , 2021 , 160, 2435-2450.e34	13.3	45
468	Views of patients with inflammatory bowel disease on the COVID-19 pandemic: a global survey. <i>The Lancet Gastroenterology and Hepatology</i> , 2020 , 5, 631-632	18.8	43
467	Comorbidities in inflammatory bowel disease: a call for action. <i>The Lancet Gastroenterology and Hepatology</i> , 2019 , 4, 643-654	18.8	43
466	Ozanimod induction therapy for patients with moderate to severe Crohn's disease: a single-arm, phase 2, prospective observer-blinded endpoint study. <i>The Lancet Gastroenterology and Hepatology</i> , 2020 , 5, 819-828	18.8	42
465	Full Interchangeability in Regard to Immunogenicity Between the Infliximab Reference Biologic and Biosimilars CT-P13 and SB2 in Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2018 , 24, 601-606	4.5	42
464	Integrated models of care in managing inflammatory bowel disease: a discussion. <i>Inflammatory Bowel Diseases</i> , 2012 , 18, 1582-7	4.5	42
463	Vedolizumab for the treatment of IBD: a selective therapeutic approach targeting pathogenic a4b7 cells. <i>Current Drug Targets</i> , 2013 , 14, 1433-43	3	42
462	Evolving therapeutic goals in ulcerative colitis: towards disease clearance. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2020 , 17, 1-2	24.2	42
461	Review article: the histological assessment of disease activity in ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2015 , 42, 957-67	6.1	41
460	Anaemia management in patients with inflammatory bowel disease: routine practice across nine European countries. <i>European Journal of Gastroenterology and Hepatology</i> , 2013 , 25, 1456-63	2.2	41
459	Colonic diverticular disease. <i>Nature Reviews Disease Primers</i> , 2020 , 6, 20	51.1	40
458	Accuracy of Humanitas Ultrasound Criteria in Assessing Disease Activity and Severity in Ulcerative Colitis: A Prospective Study. <i>Journal of Crohn's and Colitis</i> , 2018 , 12, 1385-1391	1.5	40
457	Comparative Accuracy of Bowel Ultrasound Versus Magnetic Resonance Enterography in Combination With Colonoscopy in Assessing Crohn's Disease and Guiding Clinical Decision-making. <i>Journal of Crohn's and Colitis</i> , 2018 , 12, 1280-1287	1.5	39
456	Anaemia from a patient perspective in inflammatory bowel disease: results from the European Federation of Crohn's and Ulcerative Colitis Association's online survey. <i>European Journal of Gastroenterology and Hepatology</i> , 2014 , 26, 1385-91	2.2	39
455	Challenges to the design, execution, and analysis of randomized controlled trials for inflammatory bowel disease. <i>Gastroenterology</i> , 2012 , 143, 1461-9	13.3	39
454	Actors and Factors in the Resolution of Intestinal Inflammation: Lipid Mediators As a New Approach to Therapy in Inflammatory Bowel Diseases. <i>Frontiers in Immunology</i> , 2017 , 8, 1331	8.4	38
453	Catching the therapeutic window of opportunity in early Crohn's disease. <i>Current Drug Targets</i> , 2014 , 15, 1056-63	3	38

452	Revisiting the gut-joint axis: links between gut inflammation and spondyloarthritis. <i>Nature Reviews Rheumatology</i> , 2020 , 16, 415-433	8.1	38
451	Systematic Review on Inflammatory Bowel Disease Patients With Coronavirus Disease 2019: It Is Time to Take Stock. <i>Clinical Gastroenterology and Hepatology</i> , 2020 , 18, 2689-2700	6.9	38
450	Ulcerative Colitis and Crohn's Disease Have Similar Burden and Goals for Treatment. <i>Clinical Gastroenterology and Hepatology</i> , 2020 , 18, 14-23	6.9	38
449	Bacterial sensor triggering receptor expressed on myeloid cells-2 regulates the mucosal inflammatory response. <i>Gastroenterology</i> , 2013 , 144, 346-356.e3	13.3	37
448	Advances in therapeutic interventions targeting the vascular and lymphatic endothelium in inflammatory bowel disease. <i>Current Opinion in Gastroenterology</i> , 2013 , 29, 608-13	3	37
447	Use of biosimilars in inflammatory bowel disease: Statements of the Italian Group for Inflammatory Bowel Disease. <i>Digestive and Liver Disease</i> , 2014 , 46, 963-8	3.3	36
446	Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial. <i>Lancet, The</i> , 2021 , 397, 2372-2384	4.0	36
445	Metagenomic analysis of intestinal mucosa revealed a specific eukaryotic gut virome signature in early-diagnosed inflammatory bowel disease. <i>Gut Microbes</i> , 2019 , 10, 149-158	8.8	36
444	Review article: moving towards common therapeutic goals in Crohn's disease and rheumatoid arthritis. <i>Alimentary Pharmacology and Therapeutics</i> , 2017 , 45, 1058-1072	6.1	35
443	The PROSIT Cohort of Infliximab Biosimilar in IBD: A Prolonged Follow-up on the Effectiveness and Safety Across Italy. <i>Inflammatory Bowel Diseases</i> , 2019 , 25, 568-579	4.5	35
442	Internet use among inflammatory bowel disease patients: an Italian multicenter survey. <i>European Journal of Gastroenterology and Hepatology</i> , 2009 , 21, 1036-41	2.2	35
441	COVID-19 Digestive System Involvement and Clinical Outcomes in a Large Academic Hospital in Milan, Italy. <i>Clinical Gastroenterology and Hepatology</i> , 2020 , 18, 2366-2368.e3	6.9	35
440	Colorectal cancer prevention in patients with ulcerative colitis. <i>Baillieres Best Practice and Research in Clinical Gastroenterology</i> , 2018 , 32-33, 103-109	2.5	35
439	Ozanimod as Induction and Maintenance Therapy for Ulcerative Colitis. <i>New England Journal of Medicine</i> , 2021 , 385, 1280-1291	59.2	35
438	Safety of treatments for inflammatory bowel disease: Clinical practice guidelines of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). <i>Digestive and Liver Disease</i> , 2017 , 49, 338-358	3.3	34
437	Use of corticosteroids and immunosuppressive drugs in inflammatory bowel disease: Clinical practice guidelines of the Italian Group for the Study of Inflammatory Bowel Disease. <i>Digestive and Liver Disease</i> , 2017 , 49, 604-617	3.3	34
436	Activation of the VEGFC/VEGFR3 Pathway Induces Tumor Immune Escape in Colorectal Cancer. <i>Cancer Research</i> , 2019 , 79, 4196-4210	10.1	34
435	ECCO Position Paper: Harmonization of the Approach to Ulcerative Colitis Histopathology. <i>Journal of Crohn's and Colitis</i> , 2020 , 14, 1503-1511	1.5	34

434	MFSD2A Promotes Endothelial Generation of Inflammation-Resolving Lipid Mediators and Reduces Colitis in Mice. <i>Gastroenterology</i> , 2017 , 153, 1363-1377.e6	13.3	34
433	Long-term safety of vedolizumab for inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2020 , 52, 1353-1365	6.1	34
432	Tofacitinib in the treatment of ulcerative colitis: efficacy and safety from clinical trials to real-world experience. <i>Therapeutic Advances in Gastroenterology</i> , 2019 , 12, 1756284819848631	4.7	33
431	Targeting S1P in Inflammatory Bowel Disease: New Avenues for Modulating Intestinal Leukocyte Migration. <i>Journal of Crohn's and Colitis</i> , 2018 , 12, S678-S686	1.5	33
430	Multimodal treatment of perianal fistulas in Crohn's disease: seton versus anti-TNF versus advancement plasty (PISA): study protocol for a randomized controlled trial. <i>Trials</i> , 2015 , 16, 366	2.8	33
429	NKp46-expressing human gut-resident intraepithelial V α 1 T cell subpopulation exhibits high antitumor activity against colorectal cancer. <i>JCI Insight</i> , 2019 , 4,	9.9	33
428	The Future of Biosimilars: Maximizing Benefits Across Immune-Mediated Inflammatory Diseases. <i>Drugs</i> , 2020 , 80, 99-113	12.1	32
427	TREM-1 Inhibition Restores Impaired Autophagy Activity and Reduces Colitis in Mice. <i>Journal of Crohn's and Colitis</i> , 2018 , 12, 230-244	1.5	32
426	Perception of Reproductive Health in Women with Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , 2016 , 10, 886-91	1.5	32
425	Gut microbiome in chronic rheumatic and inflammatory bowel diseases: Similarities and differences. <i>United European Gastroenterology Journal</i> , 2019 , 7, 1008-1032	5.3	32
424	Melanoma cell therapy: Endothelial progenitor cells as shuttle of the MMP12 uPAR-degrading enzyme. <i>Oncotarget</i> , 2014 , 5, 3711-27	3.3	32
423	A Surface Plasmon Resonance-based assay to measure serum concentrations of therapeutic antibodies and anti-drug antibodies. <i>Scientific Reports</i> , 2019 , 9, 2064	4.9	32
422	Role of Epithelial-to-Mesenchymal Transition in Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , 2019 , 13, 659-668	1.5	32
421	Approaches to Integrating Biomarkers Into Clinical Trials and Care Pathways as Targets for the Treatment of Inflammatory Bowel Diseases. <i>Gastroenterology</i> , 2019 , 157, 1032-1043.e1	13.3	31
420	Consensus report: clinical recommendations for the prevention and management of the nocebo effect in biosimilar-treated IBD patients. <i>Alimentary Pharmacology and Therapeutics</i> , 2019 , 49, 1181-1187	6.1	31
419	Liver tests abnormalities in COVID-19: trick or treat?. <i>Journal of Hepatology</i> , 2020 , 73, 1275-1276	13.4	30
418	Positioning Therapies in Ulcerative Colitis. <i>Clinical Gastroenterology and Hepatology</i> , 2020 , 18, 1280-1290.e1	6.1	30
417	Ustekinumab Pharmacokinetics and Exposure Response in a Phase 3 Randomized Trial of Patients With Ulcerative Colitis. <i>Clinical Gastroenterology and Hepatology</i> , 2020 , 18, 2244-2255.e9	6.9	30

416	Maintaining the Quality Standards of Care for Inflammatory Bowel Disease Patients During the COVID-19 Pandemic. <i>Clinical Gastroenterology and Hepatology</i> , 2020 , 18, 1882-1883	6.9	30
415	Unmet Medical Needs in Ulcerative Colitis: An Expert Group Consensus. <i>Digestive Diseases</i> , 2019 , 37, 266-283	3.2	29
414	Review article: faecal calprotectin and histologic remission in ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2020 , 51, 689-698	6.1	29
413	Fibroblast Growth Factor 19 modulates intestinal microbiota and inflammation in presence of Farnesoid X Receptor. <i>EBioMedicine</i> , 2020 , 54, 102719	8.8	29
412	Identification of Endpoints for Development of Antifibrosis Drugs for Treatment of Crohn's Disease. <i>Gastroenterology</i> , 2018 , 155, 76-87	13.3	29
411	Prevalence of Bowel Damage Assessed by Cross-Sectional Imaging in Early Crohn's Disease and its Impact on Disease Outcome. <i>Journal of Crohn's and Colitis</i> , 2017 , 11, 274-280	1.5	29
410	Expert consensus paper on the use of Vedolizumab for the management of patients with moderate-to-severe Inflammatory Bowel Disease. <i>Digestive and Liver Disease</i> , 2016 , 48, 360-70	3.3	29
409	Dose optimization is effective in ulcerative colitis patients losing response to infliximab: a collaborative multicentre retrospective study. <i>Digestive and Liver Disease</i> , 2014 , 46, 135-9	3.3	29
408	The triggering receptor expressed on myeloid cells (TREM) in inflammatory bowel disease pathogenesis. <i>Journal of Translational Medicine</i> , 2014 , 12, 293	8.5	29
407	Calcium supplementation for the prevention of colorectal adenomas: A systematic review and meta-analysis of randomized controlled trials. <i>World Journal of Gastroenterology</i> , 2016 , 22, 4594-603	5.6	29
406	Discontinuation of Infliximab in Patients With Ulcerative Colitis Is Associated With Increased Risk of Relapse: A Multinational Retrospective Cohort Study. <i>Clinical Gastroenterology and Hepatology</i> , 2016 , 14, 1426-1432.e1	6.9	28
405	Microscopic features of colorectal neoplasia in inflammatory bowel diseases. <i>World Journal of Gastroenterology</i> , 2014 , 20, 3164-72	5.6	28
404	The role of integrins in the pathogenesis of inflammatory bowel disease: Approved and investigational anti-integrin therapies. <i>Medicinal Research Reviews</i> , 2020 , 40, 245-262	14.4	28
403	Evaluation of the Cross-reactivity of Antidrug Antibodies to CT-P13 and Infliximab Reference Product (Remicade): An Analysis Using Immunoassays Tagged with Both Agents. <i>BioDrugs</i> , 2017 , 31, 223-237	7.9	27
402	Comparison between 1.5 and 3.0 Tesla magnetic resonance enterography for the assessment of disease activity and complications in ileo-colonic Crohn's disease. <i>Digestive Diseases and Sciences</i> , 2013 , 58, 3246-55	4	27
401	PDE4 Inhibition and Inflammatory Bowel Disease: A Novel Therapeutic Avenue. <i>International Journal of Molecular Sciences</i> , 2017 , 18,	6.3	27
400	Efficacy and safety of tofacitinib dose de-escalation and dose escalation for patients with ulcerative colitis: results from OCTAVE Open. <i>Alimentary Pharmacology and Therapeutics</i> , 2020 , 51, 271-280	6.1	27
399	Drug development in IBD: from novel target identification to early clinical trials. <i>Gut</i> , 2016 , 65, 1233-9	19.2	27

398	Inflammatory Bowel Diseases and COVID-19: The Invisible Enemy. <i>Gastroenterology</i> , 2020 , 158, 2302-2304	14.3	27
397	Vedolizumab Trough Levels and Histological Healing During Maintenance Therapy in Ulcerative Colitis. <i>Journal of Crohn's and Colitis</i> , 2019 , 13, 970-975	1.5	26
396	Gastroenterology department operational reorganisation at the time of covid-19 outbreak: an Italian and Chinese experience. <i>Gut</i> , 2020 , 69, 981-983	19.2	26
395	Effect of Adalimumab on Clinical Outcomes and Health-related Quality of Life Among Patients With Ulcerative Colitis in a Clinical Practice Setting: Results From Inspira. <i>Journal of Crohn's and Colitis</i> , 2017 , 11, 1317-1325	1.5	26
394	Disease patterns in late-onset ulcerative colitis: Results from the IG-IBD "AGED study". <i>Digestive and Liver Disease</i> , 2017 , 49, 17-23	3.3	26
393	Effect of tumor necrosis factor- α blockade on mucosal addressin cell-adhesion molecule-1 in Crohn's disease. <i>Inflammatory Bowel Diseases</i> , 2013 , 19, 259-64	4.5	26
392	Rho-A prenylation and signaling link epithelial homeostasis to intestinal inflammation. <i>Journal of Clinical Investigation</i> , 2016 , 126, 611-26	15.9	26
391	Management of gastrointestinal and liver diseases during pregnancy. <i>Gut</i> , 2014 , 63, 1014-23	19.2	25
390	Infection Risk With Biologic Therapy in Patients With Inflammatory Bowel Disease. <i>Clinical Pharmacology and Therapeutics</i> , 2017 , 102, 633-641	6.1	25
389	Full-length soluble urokinase plasminogen activator receptor down-modulates nephrin expression in podocytes. <i>Scientific Reports</i> , 2015 , 5, 13647	4.9	25
388	Biosimilars for the Management of Inflammatory Bowel Diseases: Economic Considerations. <i>Current Medicinal Chemistry</i> , 2019 , 26, 259-269	4.3	25
387	Treatment Persistence for Infliximab Versus Adalimumab in Crohn's Disease: A 14-Year Single-Center Experience. <i>Inflammatory Bowel Diseases</i> , 2017 , 23, 976-985	4.5	24
386	Comparative safety of systemic and low-bioavailability steroids in inflammatory bowel disease: Systematic review and network meta-analysis. <i>British Journal of Clinical Pharmacology</i> , 2018 , 84, 239-251	3.8	24
385	Predictive value of the Diverticular Inflammation and Complication Assessment (DICA) endoscopic classification on the outcome of diverticular disease of the colon: An international study. <i>United European Gastroenterology Journal</i> , 2016 , 4, 604-13	5.3	24
384	Complementary and alternative medicine in inflammatory bowel diseases: what is the future in the field of herbal medicine?. <i>Expert Review of Gastroenterology and Hepatology</i> , 2014 , 8, 835-46	4.2	24
383	The urokinase plasminogen activator receptor (uPAR) controls macrophage phagocytosis in intestinal inflammation. <i>Gut</i> , 2015 , 64, 589-600	19.2	24
382	FOXP3+ T regulatory cell modifications in inflammatory bowel disease patients treated with anti-TNF α agents. <i>BioMed Research International</i> , 2013 , 2013, 286368	3	24
381	MRI in Crohn's disease--current and future clinical applications. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2011 , 9, 23-31	24.2	24

380	Budesonide MMX for the Induction of Remission of Mild to Moderate Ulcerative Colitis: A Pooled Safety Analysis. <i>Journal of Crohn's and Colitis</i> , 2015 , 9, 738-46	1.5	23
379	Inflammatory bowel disease position statement of the Italian Society of Colorectal Surgery (SICCR): Crohn's disease. <i>Techniques in Coloproctology</i> , 2020 , 24, 421-448	2.9	23
378	Can IL-23 be a good target for ulcerative colitis?. <i>Baillieres Best Practice and Research in Clinical Gastroenterology</i> , 2018 , 32-33, 95-102	2.5	23
377	Preoperative magnetic resonance enterography in predicting findings and optimizing surgical approach in Crohn's disease. <i>Journal of Gastrointestinal Surgery</i> , 2014 , 18, 83-90; discussion 90-1	3.3	23
376	Histological Remission in Ulcerative Colitis: Under the Microscope Is the Cure. <i>American Journal of Gastroenterology</i> , 2020 , 115, 179-189	0.7	23
375	The safety of biological pharmacotherapy for the treatment of ulcerative colitis. <i>Expert Opinion on Drug Safety</i> , 2017 , 16, 437-443	4.1	22
374	Efficacy of tumour necrosis factor antagonists in stricturing Crohn's disease: A tertiary center real-life experience. <i>Digestive and Liver Disease</i> , 2017 , 49, 872-877	3.3	22
373	Use of biosimilars in inflammatory bowel disease: a position update of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). <i>Digestive and Liver Disease</i> , 2019 , 51, 632-639	3.3	22
372	Inflammatory bowel disease (IBD) position statement of the Italian Society of Colorectal Surgery (SICCR): general principles of IBD management. <i>Techniques in Coloproctology</i> , 2020 , 24, 105-126	2.9	22
371	Effectiveness Research in Inflammatory Bowel Disease: A Necessity and a Methodological Challenge. <i>Journal of Crohn's and Colitis</i> , 2016 , 10, 1096-102	1.5	22
370	Noninvasive Multimodal Methods to Differentiate Inflamed vs Fibrotic Strictures in Patients With Crohn's Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2019 , 17, 2397-2415	6.9	22
369	Treatment of Perianal Fistulas in Crohn's Disease, Seton Versus Anti-TNF Versus Surgical Closure Following Anti-TNF [PISA]: A Randomised Controlled Trial. <i>Journal of Crohn's and Colitis</i> , 2020 , 14, 1049-1056	10.56	22
368	Illness Perception in Inflammatory Bowel Disease Patients is Different Between Patients With Active Disease or in Remission: A Prospective Cohort Study. <i>Journal of Crohn's and Colitis</i> , 2019 , 13, 417-423	1.5	22
367	Modern use of 5-aminosalicylic acid compounds for ulcerative colitis. <i>Expert Opinion on Biological Therapy</i> , 2020 , 20, 363-378	5.4	22
366	Haematopoietic prolyl hydroxylase-1 deficiency promotes M2 macrophage polarization and is both necessary and sufficient to protect against experimental colitis. <i>Journal of Pathology</i> , 2017 , 241, 547-558	9.4	21
365	The biosimilar road in inflammatory bowel disease: the right way?. <i>Baillieres Best Practice and Research in Clinical Gastroenterology</i> , 2014 , 28, 465-71	2.5	21
364	Inflammatory bowel disease: estimates from the global burden of disease 2017 study. <i>Alimentary Pharmacology and Therapeutics</i> , 2020 , 51, 261-270	6.1	21
363	Sexual and reproductive issues and inflammatory bowel disease: a neglected topic in men. <i>European Journal of Gastroenterology and Hepatology</i> , 2018 , 30, 316-322	2.2	20

362	Safety of biological therapies in ulcerative colitis: An umbrella review of meta-analyses. <i>Baillieres Best Practice and Research in Clinical Gastroenterology</i> , 2018 , 32-33, 43-47	2.5	20
361	Role of bowel ultrasound as a predictor of surgical recurrence of Crohn's disease. <i>Scandinavian Journal of Gastroenterology</i> , 2013 , 48, 552-5	2.4	20
360	Integrins and adhesion molecules as targets to treat inflammatory bowel disease. <i>Current Opinion in Pharmacology</i> , 2015 , 25, 67-71	5.1	20
359	Roseburia hominis: a novel guilty player in ulcerative colitis pathogenesis?. <i>Gut</i> , 2014 , 63, 1204-5	19.2	20
358	Anti-IL-13 in inflammatory bowel disease: from the bench to the bedside. <i>Current Drug Targets</i> , 2013 , 14, 1444-52	3	20
357	Head-to-head trials in inflammatory bowel disease: past, present and future. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2020 , 17, 365-376	24.2	20
356	Vedolizumab Treatment in Extra-Intestinal Manifestations in Inflammatory Bowel Disease: A Systematic Review. <i>Journal of Crohn's and Colitis</i> , 2019 , 13, 1569-1577	1.5	19
355	Direct retrospective comparison of adalimumab and infliximab in preventing early postoperative endoscopic recurrence after ileocaecal resection for crohn's disease: results from the MULTIPER database. <i>Journal of Crohn's and Colitis</i> , 2015 , 9, 541-7	1.5	19
354	Review article: treating-to-target for inflammatory bowel disease-associated anaemia. <i>Alimentary Pharmacology and Therapeutics</i> , 2018 , 48, 610-617	6.1	19
353	Prevention and treatment of venous thromboembolism in patients with IBD: a trail still climbing. <i>Inflammatory Bowel Diseases</i> , 2015 , 21, 1204-13	4.5	19
352	Proximal collagenous gastroenteritides: clinical management. A systematic review. <i>Annals of Medicine</i> , 2014 , 46, 311-7	1.5	19
351	Increased expression of CD133 is a strong predictor of poor outcome in stage I colorectal cancer patients. <i>Scandinavian Journal of Gastroenterology</i> , 2012 , 47, 1211-7	2.4	19
350	Gastrointestinal involvement attenuates COVID-19 severity and mortality 2020 ,		19
349	OP34 VARSITY: A double-blind, double-dummy, randomised, controlled trial of vedolizumab versus adalimumab in patients with active ulcerative colitis. <i>Journal of Crohn's and Colitis</i> , 2019 , 13, S612-S613	1.5	19
348	Effects of Apremilast, an Oral Inhibitor of Phosphodiesterase 4, in a Randomized Trial of Patients With Active Ulcerative Colitis. <i>Clinical Gastroenterology and Hepatology</i> , 2020 , 18, 2526-2534.e9	6.9	18
347	Cost-effectiveness of biological treatment sequences for fistulising Crohn's disease across Europe. <i>United European Gastroenterology Journal</i> , 2018 , 6, 310-321	5.3	18
346	Preventing disability in inflammatory bowel disease. <i>Therapeutic Advances in Gastroenterology</i> , 2017 , 10, 865-876	4.7	18
345	The gut virome in inflammatory bowel disease pathogenesis: From metagenomics to novel therapeutic approaches. <i>United European Gastroenterology Journal</i> , 2019 , 7, 999-1007	5.3	17

344	Patients with Inflammatory Bowel Disease Are Not at Increased Risk of COVID-19: A Large Multinational Cohort Study. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	17
343	Systematic review with meta-analysis: biologics and risk of infection or cancer in elderly patients with inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2020 , 51, 820-830	6.1	17
342	Challenges in the Pathophysiology, Diagnosis and Management of Intestinal Fibrosis in Inflammatory Bowel Disease. <i>Gastroenterology</i> , 2019 ,	13.3	17
341	Patient and physician views on the quality of care in inflammatory bowel disease: results from SOLUTION-1, a prospective IG-IBD study. <i>Journal of Crohn's and Colitis</i> , 2014 , 8, 1642-52	1.5	17
340	Use of Cross-Sectional Imaging for Tight Monitoring of Inflammatory Bowel Diseases. <i>Clinical Gastroenterology and Hepatology</i> , 2020 , 18, 1309-1323.e4	6.9	17
339	Treatments for Crohn's Disease-Associated Bowel Damage: A Systematic Review. <i>Clinical Gastroenterology and Hepatology</i> , 2019 , 17, 847-856	6.9	17
338	Fecal Calprotectin Responses Following Induction Therapy With Vedolizumab in Moderate to Severe Ulcerative Colitis: A Post Hoc Analysis of GEMINI 1. <i>Inflammatory Bowel Diseases</i> , 2019 , 25, 803-810	4.5	17
337	The role of multimodal treatment in Crohn's disease patients with perianal fistula: a multicentre retrospective cohort study. <i>Alimentary Pharmacology and Therapeutics</i> , 2018 , 48, 941-950	6.1	17
336	Inflammatory bowel disease position statement of the Italian Society of Colorectal Surgery (SICCR): ulcerative colitis. <i>Techniques in Coloproctology</i> , 2020 , 24, 397-419	2.9	16
335	Accuracy of Diffusion-weighted Magnetic Resonance Imaging in Detecting Mucosal Healing and Treatment Response, and in Predicting Surgery, in Crohn's Disease. <i>Journal of Crohn's and Colitis</i> , 2018 , 12, 1180-1190	1.5	16
334	Antigenic response to CT-P13 and infliximab originator in inflammatory bowel disease patients shows similar epitope recognition. <i>Alimentary Pharmacology and Therapeutics</i> , 2018 , 48, 507-522	6.1	16
333	The management of iron deficiency in inflammatory bowel disease--an online tool developed by the RAND/UCLA appropriateness method. <i>Alimentary Pharmacology and Therapeutics</i> , 2013 , 38, 1109-18	6.1	16
332	E-health in inflammatory bowel diseases: More challenges than opportunities?. <i>Digestive and Liver Disease</i> , 2017 , 49, 1320-1326	3.3	16
331	Anti-TNF and skin inflammation in IBD: a new paradox in gastroenterology?. <i>Gut</i> , 2014 , 63, 533-5	19.2	16
330	SARS-CoV-2 vaccination in IBD: more pros than cons. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2021 , 18, 211-213	24.2	16
329	Unmet Needs in IBD: the Case of Fatigue. <i>Clinical Reviews in Allergy and Immunology</i> , 2018 , 55, 368-378	12.3	15
328	The clinical potential of etrolizumab in ulcerative colitis: hypes and hopes. <i>Therapeutic Advances in Gastroenterology</i> , 2016 , 9, 503-12	4.7	15
327	Preventing Collateral Damage in Crohn's Disease: The Lhann Index. <i>Journal of Crohn's and Colitis</i> , 2016 , 10, 495-500	1.5	15

326	The impact of biologics in surgical outcomes in ulcerative colitis. <i>Baillieres Best Practice and Research in Clinical Gastroenterology</i> , 2018 , 32-33, 79-87	2.5	15
325	Ustekinumab is effective and safe for ulcerative colitis through 2 years of maintenance therapy. <i>Alimentary Pharmacology and Therapeutics</i> , 2020 , 52, 1658-1675	6.1	15
324	Clinician Education and Adoption of Preventive Measures for COVID-19: A Survey of a Convenience Sample of General Practitioners in Lombardy, Italy. <i>Annals of Internal Medicine</i> , 2020 , 173, 405-407	8	15
323	Changes in inflammatory bowel disease patients' perspectives on biosimilars: A follow-up survey. <i>United European Gastroenterology Journal</i> , 2019 , 7, 1345-1352	5.3	15
322	Dual Targeted Therapy: a possible option for the management of refractory Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , 2020 ,	1.5	15
321	Andecaliximab [Anti-matrix Metalloproteinase-9] Induction Therapy for Ulcerative Colitis: A Randomised, Double-Blind, Placebo-Controlled, Phase 2/3 Study in Patients With Moderate to Severe Disease. <i>Journal of Crohn's and Colitis</i> , 2018 , 12, 1021-1029	1.5	15
320	JAK inhibitors: Novel developments in management of ulcerative colitis. <i>Baillieres Best Practice and Research in Clinical Gastroenterology</i> , 2018 , 32-33, 89-93	2.5	15
319	Disease-related and drug-induced skin manifestations in inflammatory bowel disease. <i>Expert Review of Gastroenterology and Hepatology</i> , 2017 , 11, 203-214	4.2	14
318	Ustekinumab in the management of Crohn's disease: Expert opinion. <i>Digestive and Liver Disease</i> , 2018 , 50, 653-660	3.3	14
317	TNF α inhibitors restrict T cell activation and cycling via Notch-1 signalling in inflammatory bowel disease. <i>Gut</i> , 2012 , 61, 1016-27	19.2	14
316	Endothelial Cell-Immune Cell Interaction in IBD. <i>Digestive Diseases</i> , 2016 , 34, 43-50	3.2	14
315	Efficacy and safety of biologic agents and tofacitinib in moderate-to-severe ulcerative colitis: A systematic overview of meta-analyses. <i>United European Gastroenterology Journal</i> , 2019 , 7, 1285-1303	5.3	14
314	Effectiveness of golimumab in ulcerative colitis: A review of the real world evidence. <i>Digestive and Liver Disease</i> , 2019 , 51, 327-334	3.3	14
313	Positioning Ustekinumab in Crohn's Disease: From Clinical Evidence to Clinical Practice. <i>Journal of Crohn's and Colitis</i> , 2017 , 11, 1258-1266	1.5	13
312	SFED recommendations for IBD endoscopy during COVID-19 pandemic: Italian and French experience. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2020 , 17, 507-516	24.2	13
311	Diffusion-weighted MRI in inflammatory bowel disease. <i>The Lancet Gastroenterology and Hepatology</i> , 2018 , 3, 433-443	18.8	13
310	Improving the quality of surveillance colonoscopy in inflammatory bowel disease. <i>The Lancet Gastroenterology and Hepatology</i> , 2019 , 4, 971-983	18.8	13
309	Multidisciplinary management of the nocebo effect in biosimilar-treated IBD patients: Results of a workshop from the NOCE-BIO consensus group. <i>Digestive and Liver Disease</i> , 2020 , 52, 138-142	3.3	13

308	Biosimilars of adalimumab: the upcoming challenge in IBD. <i>Expert Opinion on Biological Therapy</i> , 2019 , 19, 1023-1030	5.4	13
307	Comparison of the EMA and FDA Guidelines on Ulcerative Colitis Drug Development. <i>Clinical Gastroenterology and Hepatology</i> , 2019 , 17, 1673-1679.e1	6.9	13
306	IL-23 Blockade for Crohn's disease: next generation of anti-cytokine therapy. <i>Expert Review of Clinical Immunology</i> , 2017 , 13, 457-467	5.1	12
305	Superior Endoscopic and Deep Remission Outcomes in Adults with Moderate to Severe Crohn's Disease Managed with Treat to Target Approach Versus Clinical Symptoms: Data from Calm. <i>Gastroenterology</i> , 2017 , 152, S155	13.3	12
304	OP35 Endoscopic and deep remission at 1 year prevents disease progression in early Crohn's disease: long-term data from CALM. <i>Journal of Crohn's and Colitis</i> , 2019 , 13, S024-S025	1.5	12
303	OP37 Efficacy and safety of ustekinumab as maintenance therapy in ulcerative colitis: Week 44 results from UNIFI. <i>Journal of Crohn's and Colitis</i> , 2019 , 13, S025-S026	1.5	12
302	Progress with anti-tumor necrosis factor therapeutics for the treatment of inflammatory bowel disease. <i>Immunotherapy</i> , 2015 , 7, 175-90	3.8	12
301	Biosimilars - terms of use. <i>Current Medical Research and Opinion</i> , 2015 , 31, 2325-30	2.5	12
300	The day after COVID-19 in IBD: how to go back to 'normal'. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2020 , 17, 441-443	24.2	12
299	Association of Biomarker Cutoffs and Endoscopic Outcomes in Crohn's Disease: A Post Hoc Analysis From the CALM Study. <i>Inflammatory Bowel Diseases</i> , 2020 , 26, 1562-1571	4.5	12
298	Filgotinib in Crohn's Disease: JAK Is Back. <i>Gastroenterology</i> , 2017 , 153, 603-605	13.3	12
297	Guselkumab for the treatment of Crohn's disease: Induction results from the Phase 2 GALAXI-1 study.. <i>Gastroenterology</i> , 2022 ,	13.3	12
296	Darvadstrocel for the treatment of patients with perianal fistulas in Crohn's disease. <i>Drugs of Today</i> , 2019 , 55, 95-105	2.5	12
295	Long-term Safety of Vedolizumab for the Treatment of Ulcerative Colitis or Crohn's Disease. <i>American Journal of Gastroenterology</i> , 2013 , 108, S502-S503	0.7	12
294	Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis. <i>The Lancet Gastroenterology and Hepatology</i> , 2021 ,	18.8	12
293	Early Intervention in Ulcerative Colitis: Ready for Prime Time?. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	12
292	Psychological Characteristics of Inflammatory Bowel Disease Patients: A Comparison Between Active and Nonactive Patients. <i>Inflammatory Bowel Diseases</i> , 2019 , 25, 1399-1407	4.5	11
291	Lymphatic endothelium contributes to colorectal cancer growth via the soluble matrisome component GDF11. <i>International Journal of Cancer</i> , 2019 , 145, 1913-1920	7.5	11

290	Positioning Tofacitinib in the Treatment Algorithm of Moderate to Severe Ulcerative Colitis. <i>Inflammatory Bowel Diseases</i> , 2018 , 24, 2106-2112	4.5	11
289	Management of patients with inflammatory bowel disease and spondyloarthritis. <i>Expert Review of Clinical Pharmacology</i> , 2017 , 10, 1363-1374	3.8	11
288	Effectiveness of Mesalazine, Thiopurines and Tumour Necrosis Factor Antagonists in Preventing Post-Operative Crohn's Disease Recurrence in a Real-Life Setting. <i>Digestion</i> , 2017 , 96, 166-172	3.6	11
287	Review article: The pharmacokinetics and pharmacodynamics of drugs used in inflammatory bowel disease treatment. <i>European Journal of Clinical Pharmacology</i> , 2015 , 71, 773-99	2.8	11
286	Letter: infliximab therapy in inflammatory bowel disease patients after liver transplantation. <i>Alimentary Pharmacology and Therapeutics</i> , 2013 , 37, 840-2	6.1	11
285	Imaging modalities for perianal Crohn's disease. <i>Current Drug Targets</i> , 2012 , 13, 1287-93	3	11
284	Consensus recommendations for patient-centered therapy in mild-to-moderate ulcerative colitis: the i Support Therapy-Access to Rapid Treatment (iSTART) approach. <i>Intestinal Research</i> , 2018 , 16, 522-528	4.1	11
283	Treatment Persistence of Infliximab Versus Adalimumab in Ulcerative Colitis: A 16-Year Single-Center Experience. <i>Inflammatory Bowel Diseases</i> , 2019 , 25, 945-954	4.5	11
282	Aortic Stiffening Is an Extraintestinal Manifestation of Inflammatory Bowel Disease: Review of the Literature and Expert Panel Statement. <i>Angiology</i> , 2020 , 71, 689-697	2.1	11
281	TNF Inhibitors and Risk of Malignancy in Patients with Inflammatory Bowel Diseases: A Systematic Review. <i>Journal of Crohn's and Colitis</i> , 2021 , 15, 840-859	1.5	11
280	New targeted therapies such as anti-adhesion molecules, anti-IL-12/23 and anti-Janus kinases are looking toward a more effective treatment of inflammatory bowel disease. <i>Scandinavian Journal of Gastroenterology</i> , 2015 , 50, 113-20	2.4	10
279	Anti-TNF biosimilars in Crohn's Disease: a patient-centric interdisciplinary approach. <i>Expert Review of Gastroenterology and Hepatology</i> , 2019 , 13, 731-738	4.2	10
278	Safety and efficacy of sodium hyaluronate (IBD98E) in the induction of clinical and endoscopic remission in subjects with distal ulcerative colitis. <i>Digestive and Liver Disease</i> , 2014 , 46, 330-4	3.3	10
277	Are Surgical Rates Decreasing in the Biological Era In IBD?. <i>Current Drug Targets</i> , 2019 , 20, 1356-1362	3	10
276	Treatment with a Urokinase Receptor-derived Cyclized Peptide Improves Experimental Colitis by Preventing Monocyte Recruitment and Macrophage Polarization. <i>Inflammatory Bowel Diseases</i> , 2016 , 22, 2390-401	4.5	10
275	A Practical Guide for Faecal Calprotectin Measurement: Myths and Realities. <i>Journal of Crohn's and Colitis</i> , 2021 , 15, 152-161	1.5	10
274	DOP48 Amiselimod, a selective S1P receptor modulator in Crohn's disease patients: a proof-of-concept study. <i>Journal of Crohn's and Colitis</i> , 2019 , 13, S055-S056	1.5	9
273	Modulation of sphingosine-1-phosphate in ulcerative colitis. <i>Expert Opinion on Biological Therapy</i> , 2020 , 20, 413-420	5.4	9

272	Adalimumab in ulcerative colitis: ready for prime time. <i>Digestive and Liver Disease</i> , 2013 , 45, 8-13	3.3	9
271	Cross-sectional imaging modalities in Crohn's disease. <i>Digestive Diseases</i> , 2013 , 31, 199-201	3.2	9
270	Management of patients with complex perianal fistulas in Crohn's disease: Optimal patient flow in the Italian clinical reality. <i>Digestive and Liver Disease</i> , 2020 , 52, 506-515	3.3	9
269	In the Presence of Conceptual Heterogeneity, Results of Network Meta-analysis Comparing Therapies in Crohn's Disease Need to Be Interpreted With Caution. <i>Gastroenterology</i> , 2015 , 148, 1483-4	13.3	8
268	Urokinase Receptor Promotes Skin Tumor Formation by Preventing Epithelial Cell Activation of Notch1. <i>Cancer Research</i> , 2015 , 75, 4895-909	10.1	8
267	Comparative accuracy of ferritin, transferrin saturation and soluble transferrin receptor for the diagnosis of iron deficiency in inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2020 , 51, 1087-1095	6.1	8
266	Adherence to infliximab therapy in inflammatory bowel disease patients in a real-life setting. <i>Journal of Digestive Diseases</i> , 2017 , 18, 566-573	3.3	8
265	IBD: To switch or not to switch: that is the biosimilar question. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2017 , 14, 508-509	24.2	8
264	Maximizing the diagnostic information from biopsies in chronic inflammatory bowel diseases: recommendations from the Erlangen International Consensus Conference on Inflammatory Bowel Diseases and presentation of the IBD-DCA score as a proposal for a new index for histologic activity assessment in ulcerative colitis and Crohn's disease. <i>Virchows Archiv Fur Pathologische Anatomie</i>	5.1	8
263	Faecal Calprotectin for the Diagnosis of Bowel Inflammation in Patients With Rheumatological Diseases: A Systematic Review. <i>Journal of Crohn's and Colitis</i> , 2020 , 14, 688-693	1.5	8
262	Histological healing: should it be considered as a new outcome for ulcerative colitis?. <i>Expert Opinion on Biological Therapy</i> , 2020 , 20, 407-412	5.4	8
261	Selective Tyrosine Kinase 2 Inhibition for Treatment of Inflammatory Bowel Disease: New Hope on the Rise. <i>Inflammatory Bowel Diseases</i> , 2021 , 27, 2023-2030	4.5	8
260	Combination therapy in inflammatory bowel disease - from traditional immunosuppressors towards the new paradigm of dual targeted therapy. <i>Autoimmunity Reviews</i> , 2021 , 20, 102832	13.6	8
259	Long-term Safety and Efficacy of the Anti-MAdCAM-1 Monoclonal Antibody Ontamalimab [SHP647] for the Treatment of Ulcerative Colitis: The Open-label Study TURANDOT II. <i>Journal of Crohn's and Colitis</i> , 2021 , 15, 938-949	1.5	8
258	Efficacy and Safety of Subcutaneous Vedolizumab in Patients With Moderately to Severely Active Crohn's Disease: Results From the VISIBLE 2 Randomised Trial. <i>Journal of Crohn's and Colitis</i> , 2021 ,	1.5	8
257	A Phase 2a, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Trial of IBD98-M Delayed-Release Capsules to Induce Remission in Patients with Active and Mild to Moderate Ulcerative Colitis. <i>Cells</i> , 2019 , 8,	7.9	7
256	Impact of therapies on bowel damage in Crohn's disease. <i>United European Gastroenterology Journal</i> , 2020 , 8, 410-417	5.3	7
255	Vedolizumab Efficacy, Safety, and Pharmacokinetics With Reduced Frequency of Dosing From Every 4 Weeks to Every 8 Weeks in Patients With Crohn's Disease or Ulcerative Colitis. <i>Journal of Crohn's and Colitis</i> , 2020 , 14, 1066-1073	1.5	7

254	Addition of Granulocyte/Monocyte Apheresis to Oral Prednisone for Steroid-dependent Ulcerative Colitis: A Randomized Multicentre Clinical Trial. <i>Journal of Crohn's and Colitis</i> , 2018 , 12, 687-694	1.5	7
253	Effectiveness of budesonide MMX (Cortiment) for the treatment of mild-to-moderate active ulcerative colitis: study protocol for a prospective multicentre observational cohort study. <i>BMJ Open Gastroenterology</i> , 2016 , 3, e000092	3.9	7
252	Should we use anti-tumor necrosis factor agents or vedolizumab as first-line biological therapy in ulcerative colitis?. <i>Baillieres Best Practice and Research in Clinical Gastroenterology</i> , 2018 , 32-33, 17-25	2.5	7
251	EMA response to ECCO position statement on biosimilars. <i>Journal of Crohn's and Colitis</i> , 2014 , 8, 259	1.5	7
250	Long-Term Effectiveness and Safety of Vedolizumab in Patients with Ulcerative Colitis: 5-Year Cumulative Exposure of Gemini 1 Completers Rolling into the Gemini Open-Label Extension Study. <i>Gastroenterology</i> , 2017 , 152, S602	13.3	7
249	Letter: immunogenicity of infliximab originator vs. CT-P13 in IBD patients. <i>Alimentary Pharmacology and Therapeutics</i> , 2017 , 46, 903-905	6.1	7
248	Blockade of lymphocyte trafficking in inflammatory bowel diseases therapy: importance of specificity of endothelial target. <i>Expert Review of Clinical Immunology</i> , 2014 , 10, 885-95	5.1	7
247	Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 study. <i>The Lancet Gastroenterology and Hepatology</i> , 2021 ,	18.8	7
246	The Experience with Biosimilars of Infliximab in Inflammatory Bowel Disease. <i>Current Pharmaceutical Design</i> , 2017 , 23, 6759-6769	3.3	7
245	Anti-TNF and Postoperative Complications in Abdominal Crohn's Disease Surgery. <i>Current Drug Targets</i> , 2019 , 20, 1339-1348	3	7
244	Late-onset Crohn's disease: a comparison of disease behaviour and therapy with younger adult patients: the Italian Group for the Study of Inflammatory Bowel Disease 'AGED' study. <i>European Journal of Gastroenterology and Hepatology</i> , 2019 , 31, 1361-1369	2.2	7
243	OP23 Efficacy and safety of vedolizumab SC in patients with moderately to severely active Crohn's disease: Results of the VISIBLE 2 study. <i>Journal of Crohn's and Colitis</i> , 2020 , 14, S020-S021	1.5	7
242	Efficacy and Safety of 2 Vedolizumab Intravenous Regimens for Perianal Fistulizing Crohn's Disease: ENTERPRISE Study. <i>Clinical Gastroenterology and Hepatology</i> , 2021 ,	6.9	7
241	Gut eukaryotic virome in colorectal carcinogenesis: Is that a trigger?. <i>Computational and Structural Biotechnology Journal</i> , 2021 , 19, 16-28	6.8	7
240	Vedolizumab treatment persistence and safety in a 2-year data analysis of an extended access programme. <i>Alimentary Pharmacology and Therapeutics</i> , 2021 , 53, 265-272	6.1	7
239	OP26 Long-term safety of vedolizumab in ulcerative colitis and Crohn's disease: final results from the GEMINI LTS study. <i>Journal of Crohn's and Colitis</i> , 2019 , 13, S018-S020	1.5	6
238	Clinical course of COVID-19 in 41 patients with immune-mediated inflammatory diseases: Experience from humanitas center, Milan. <i>Pharmacological Research</i> , 2020 , 160, 105061	10.2	6
237	Positioning ustekinumab in moderate-to-severe ulcerative colitis: new kid on the block. <i>Expert Opinion on Biological Therapy</i> , 2020 , 20, 421-427	5.4	6

236	Vedolizumab for the treatment of Crohn's disease. <i>Expert Review of Clinical Immunology</i> , 2018 , 14, 179-189	5.9	6
235	764 Results of Andante, a Randomized Clinical Study With an Anti-IL6 Antibody (PF-04236921) in Subjects With Crohn's Disease Who Are Anti-TNF Inadequate Responders. <i>Gastroenterology</i> , 2016 , 150, S155	13.3	6
234	mTOR-Dependent Stimulation of Orchestrates Immune Cell Trafficking through Lymphatic Endothelium in Patients with Crohn's Disease. <i>Cells</i> , 2019 , 8,	7.9	6
233	Correlation of Stool Frequency and Abdominal Pain Measures With Simple Endoscopic Score for Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2020 , 26, 304-313	4.5	6
232	Centrally Determined Standardization of Flow Cytometry Methods Reduces Interlaboratory Variation in a Prospective Multicenter Study. <i>Clinical and Translational Gastroenterology</i> , 2017 , 8, e126	4.2	6
231	Letter: European Medicines Agency recommendations for allergic reactions to intravenous iron-containing medicines. <i>Alimentary Pharmacology and Therapeutics</i> , 2014 , 39, 743-4	6.1	6
230	Stopping infliximab in Crohn's disease: still an ongoing STORI. <i>Inflammatory Bowel Diseases</i> , 2012 , 18, 2201-2	4.5	6
229	The Role of Diet and Lifestyle in Early-Onset Colorectal Cancer: A Systematic Review. <i>Cancers</i> , 2021 , 13,	6.6	6
228	Biosimilars of Adalimumab in Inflammatory Bowel Disease: Are we Ready for that?. <i>Current Pharmaceutical Design</i> , 2019 , 25, 7-12	3.3	6
227	Bowel damage assessment in Crohn's disease by magnetic resonance imaging. <i>Current Drug Targets</i> , 2012 , 13, 1300-7	3	6
226	Long-term safety of approved biologics for ulcerative colitis. <i>Expert Opinion on Drug Safety</i> , 2020 , 19, 807-816	4.1	6
225	Herpes Zoster and Vaccination Strategies in Inflammatory Bowel Diseases: A Practical Guide. <i>Clinical Gastroenterology and Hepatology</i> , 2020 ,	6.9	6
224	Thiopurines' Metabolites and Drug Toxicity: A Meta-Analysis. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	6
223	New drugs in the pipeline for the treatment of inflammatory bowel diseases: what is coming?. <i>Current Opinion in Pharmacology</i> , 2020 , 55, 141-150	5.1	6
222	Setting up a Virtual Calprotectin Clinic in Inflammatory Bowel Diseases: Literature Review and Nancy Experience. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	6
221	Key Strategies to Optimize Outcomes in Mild-to-Moderate Ulcerative Colitis. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	6
220	International consensus on methodological issues in standardization of fecal calprotectin measurement in inflammatory bowel diseases. <i>United European Gastroenterology Journal</i> , 2021 , 9, 451-460	5.3	6
219	Indirect Treatment Comparison of Ustekinumab Versus Other Biologics In Moderate To Severe Crohn's Disease: A 1-Year Treatment Sequence Analysis. <i>Value in Health</i> , 2016 , 19, A576	3.3	6

218	Clinical Practice of Adalimumab and Infliximab Biosimilar Treatment in Adult Patients With Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2021 , 27, 106-122	4.5	6
217	Point-of-Care Ultrasound in Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , 2021 , 15, 143-151	5.5	6
216	Innovative approaches to biologic development on the trail of CT-P13: biosimilars, value-added medicines, and biobetters. <i>MAbs</i> , 2021 , 13, 1868078	6.6	6
215	Transmural healing as a therapeutic goal in Crohn's disease: a systematic review. <i>The Lancet Gastroenterology and Hepatology</i> , 2021 , 6, 659-667	18.8	6
214	Interleukin-23 Blockers: Born to be First-line Biologic Agents in Inflammatory Bowel Disease?. <i>Current Pharmaceutical Design</i> , 2019 , 25, 25-31	3.3	5
213	Emerging therapies for the treatment of ulcerative colitis. <i>Expert Opinion on Emerging Drugs</i> , 2020 , 1-9	3.7	5
212	Infliximab biosimilar CT-P13 for inflammatory bowel disease. <i>The Lancet Gastroenterology and Hepatology</i> , 2018 , 3, 373-375	18.8	5
211	Emerging therapeutic targets and strategies in Crohn's disease. <i>Expert Review of Gastroenterology and Hepatology</i> , 2016 , 10, 735-44	4.2	5
210	Serum Bile Acids Profiling in Inflammatory Bowel Disease Patients Treated with Anti-TNFs. <i>Cells</i> , 2019 , 8,	7.9	5
209	A multicentre prospective cohort study assessing the effectiveness of budesonide MMX [®] (Cortiment [®]) for active, mild-to-moderate ulcerative colitis. <i>United European Gastroenterology Journal</i> , 2019 , 7, 1171-1182	5.3	5
208	Comparative assessment of budesonide-MMX and mesalamine in active, mild-to-moderate ulcerative colitis: A systematic review and network meta-analysis. <i>British Journal of Clinical Pharmacology</i> , 2019 , 85, 2244-2254	3.8	5
207	Commentary: anaemia in inflammatory bowel disease--the most common and ignored extra intestinal manifestation. <i>Alimentary Pharmacology and Therapeutics</i> , 2014 , 39, 227-8	6.1	5
206	Reductions in Corticosteroid Use in Patients with Ulcerative Colitis or Crohn's Disease Treated with Vedolizumab. <i>American Journal of Gastroenterology</i> , 2013 , 108, S503	0.7	5
205	IBD in 2013: enriching the therapeutic armamentarium for IBD. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2014 , 11, 84-6	24.2	5
204	OP011 Tralokinumab (CAT-354), an interleukin 13 antibody, in moderate to severe ulcerative colitis: A phase 2 randomized placebo-controlled study. <i>Journal of Crohn's and Colitis</i> , 2014 , 8, S7-S8	1.5	5
203	Mesenchymal stromal cells in inflammatory bowel disease: conspirators within the 'colitogenic niche'?. <i>Gut</i> , 2013 , 62, 1098-9	19.2	5
202	Safety and efficacy of tofacitinib for treatment of ulcerative colitis: final analysis of OCTAVE Open, an open-label, long-term extension study with up to 7.0 years of treatment. <i>Alimentary Pharmacology and Therapeutics</i> , 2021 ,	6.1	5
201	Anti-TNF Biosimilars in Inflammatory Bowel Disease: Searching the Proper Patient's Profile. <i>Current Medicinal Chemistry</i> , 2019 , 26, 280-287	4.3	5

200	Oral Iron for IBD Patients: Lessons Learned at Time of COVID-19 Pandemic. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	5
199	Treat to target or 'treat to clear' in inflammatory bowel diseases: one step further?. <i>Expert Review of Gastroenterology and Hepatology</i> , 2020 , 14, 807-817	4.2	5
198	The Role of Pro-Resolving Lipid Mediators in Colorectal Cancer-Associated Inflammation: Implications for Therapeutic Strategies. <i>Cancers</i> , 2020 , 12,	6.6	5
197	Assessment of extraintestinal manifestations in inflammatory bowel diseases: A systematic review and a proposed guide for clinical trials. <i>United European Gastroenterology Journal</i> , 2020 , 8, 1013-1030	5.3	5
196	Biosimilar switching in inflammatory bowel disease: from evidence to clinical practice. <i>Expert Review of Clinical Immunology</i> , 2020 , 16, 1019-1028	5.1	5
195	439 The PROSIT-BIO Cohort of the IG-IBD: A Prospective Observational Study of Patients With Inflammatory Bowel Disease Treated With Infliximab BioSimilar. <i>Gastroenterology</i> , 2016 , 150, S92	13.3	5
194	Environmental, Nutritional, and Socioeconomic Determinants of IBD Incidence: A Global Ecological Study. <i>Journal of Crohn's and Colitis</i> , 2020 , 14, 323-331	1.5	5
193	Incidence, Prevalence, and Clinical Epidemiology of Inflammatory Bowel Disease in the Arab World: A Systematic Review and Meta-Analysis. <i>Inflammatory Intestinal Diseases</i> , 2021 , 6, 123-131	2.5	5
192	The Brain-Gut Axis: Psychological Functioning and Inflammatory Bowel Diseases. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	5
191	The Inflammatory Bowel Disease Transcriptome and Metatranscriptome Meta-Analysis (IBD TaMMA) framework. <i>Nature Computational Science</i> , 2021 , 1, 511-515		5
190	International consensus on the prevention of venous and arterial thrombotic events in patients with inflammatory bowel disease. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2021 , 18, 857-873	24.2	5
189	Unmet Medical Needs in the Management of Ulcerative Colitis: Results of an Italian Delphi Consensus. <i>Gastroenterology Research and Practice</i> , 2019 , 2019, 3108025	2	4
188	DOP49 Efficacy of the anti-mucosal addressin cell adhesion molecule-1 (MAdCAM-1) antibody SHP647 in ulcerative colitis: results from the open-label extension study TURANDOT II. <i>Journal of Crohn's and Colitis</i> , 2019 , 13, S056-S057	1.5	4
187	DOP54 Efficacy and safety of ustekinumab through Week 16 in patients with moderate-to-severe ulcerative colitis randomised to ustekinumab: results from the UNIFI induction trial. <i>Journal of Crohn's and Colitis</i> , 2019 , 13, S061-S062	1.5	4
186	Detection and management of early stage inflammatory bowel disease: an update for clinicians. <i>Expert Review of Gastroenterology and Hepatology</i> , 2019 , 13, 547-555	4.2	4
185	Targeting SMAD7 in Crohn's Disease by Mongersen: Therapeutic Revolution Under Way?. <i>Gastroenterology</i> , 2015 , 149, 1121-3	13.3	4
184	Targeting the gut layers in Crohn's disease: mucosal or transmural healing?. <i>Expert Review of Gastroenterology and Hepatology</i> , 2020 , 14, 775-787	4.2	4
183	Clinical Trials for Inflammatory Bowel Disease: Global Guidance During the COVID-19 Pandemic. <i>Journal of Crohn's and Colitis</i> , 2020 , 14, S815-S819	1.5	4

182	Statins and inflammatory bowel disease: Where do we stand?. <i>European Journal of Internal Medicine</i> , 2020 , 75, 10-14	3.9	4
181	DOP13 Clinical and endoscopic response to ustekinumab in Crohn's disease: Week 16 interim analysis of the STARDUST trial. <i>Journal of Crohn's and Colitis</i> , 2020 , 14, S049-S052	1.5	4
180	Efficacy of anti-TNF drugs in patients with stricturing Crohn's disease. <i>Expert Review of Gastroenterology and Hepatology</i> , 2020 , 14, 347-353	4.2	4
179	Physicians' perspective on the clinical meaningfulness of inflammatory bowel disease trial results: an International Organization for the Study of Inflammatory Bowel Disease (IOIBD) survey. <i>Alimentary Pharmacology and Therapeutics</i> , 2018 , 47, 773-783	6.1	4
178	Are We Ready to Abandon Placebo in Randomised Clinical Trials for Inflammatory Bowel Disease? Pros and Cons. <i>Journal of Crohn's and Colitis</i> , 2016 , 10 Suppl 2, S548-52	1.5	4
177	Inflammatory bowel diseases and psychological issues: A new approach for a systematic analysis of the academic debate. <i>Psychology, Health and Medicine</i> , 2014 , 19, 559-71	2.1	4
176	Vedolizumab Maintenance Therapy for Ulcerative Colitis: Results of GEMINI I, a Randomized, Placebo-Controlled, Double-Blind, Multicenter Phase 3 Trial. <i>American Journal of Gastroenterology</i> , 2012 , 107, S609-S610	0.7	4
175	The prophylactic use of endoscopic vacuum therapy for anastomotic dehiscence after rectal anterior resection: is it feasible for redo surgery?. <i>Techniques in Coloproctology</i> , 2022 , 26, 319	2.9	4
174	Endoscopic and Clinical Efficacy Demonstrated With Oral Ozanimod in Moderately to Severely Active Crohn's Disease. <i>American Journal of Gastroenterology</i> , 2017 , 112, S371	0.7	4
173	Is there a role for therapeutic sphingolipids in inflammatory bowel disease?. <i>Expert Review of Gastroenterology and Hepatology</i> , 2020 , 14, 47-54	4.2	4
172	Safety of S1P Modulators in Patients with Immune-Mediated Diseases: A Systematic Review and Meta-Analysis. <i>Drug Safety</i> , 2021 , 44, 645-660	5.1	4
171	Validation of the 'Inflammatory Bowel Disease-Distribution, Chronicity, Activity [IBD-DCA] Score' for Ulcerative Colitis and Crohn's Disease. <i>Journal of Crohn's and Colitis</i> , 2021 , 15, 1621-1630	1.5	4
170	Anti-TL1A Antibody PF-06480605 Safety and Efficacy for Ulcerative Colitis: A Phase 2a Single-Arm Study. <i>Clinical Gastroenterology and Hepatology</i> , 2021 , 19, 2324-2332.e6	6.9	4
169	Adalimumab for the treatment of pediatric Crohn's disease. <i>Expert Review of Clinical Immunology</i> , 2015 , 11, 963-72	5.1	3
168	The trend of C-Reactive protein allows a safe early discharge after surgery for Crohn's disease. <i>Updates in Surgery</i> , 2020 , 72, 985-989	2.9	3
167	Challenges and opportunities for IBD drug development: from early stage to regulatory approval. <i>Gut</i> , 2020 , 69, 1157-1161	19.2	3
166	Vedolizumab and etrolizumab for ulcerative colitis: twins or simple cousins?. <i>Expert Opinion on Biological Therapy</i> , 2020 , 20, 353-361	5.4	3
165	Transmural Histological Scoring Systems in Crohn's Disease: A Systematic Review With Assessment of Methodological Quality and Operating Properties. <i>Journal of Crohn's and Colitis</i> , 2020 , 14, 743-756	1.5	3

164	PF-00547659 for the treatment of Crohn's disease and ulcerative colitis. <i>Expert Opinion on Investigational Drugs</i> , 2018 , 27, 623-629	5.9	3
163	DOP078 Are IBD specialists aware of biosimilar monoclonal antibodies? Results from a survey among ECCO members. <i>Journal of Crohn's and Colitis</i> , 2014 , 8, S53	1.5	3
162	P303 Ulcerative colitis (UC) in the elderly [Moderate at onset but then a milder course? An IG-IBD study. <i>Journal of Crohn's and Colitis</i> , 2014 , 8, S190-S191	1.5	3
161	The role of magnetic resonance imaging in detecting intestinal fibrosis in Crohn's disease. <i>Current Drug Targets</i> , 2012 , 13, 1273-9	3	3
160	Ustekinumab in Crohn's Disease: New Data for Positioning in Treatment Algorithm.. <i>Journal of Crohn's and Colitis</i> , 2022 , 16, ii30-ii41	1.5	3
159	Higher vs Standard Adalimumab Induction Dosing Regimens and 2 Maintenance Strategies: Randomized SERENE CD Trial Results.. <i>Gastroenterology</i> , 2022 ,	13.3	3
158	Golimumab: clinical update on its use for ulcerative colitis. <i>Drugs of Today</i> , 2015 , 51, 171-84	2.5	3
157	Vedolizumab treatment persistence and safety in a 2-year data analysis of an extended access programme. <i>Alimentary Pharmacology and Therapeutics</i> , 2021 , 53, 265-272	6.1	3
156	Tumour necrosis factor inhibitors in inflammatory bowel disease: the story continues.. <i>Therapeutic Advances in Gastroenterology</i> , 2021 , 14, 17562848211059954	4.7	3
155	Biosimilar-to-Biosimilar Switching: What is the Rationale and Current Experience?. <i>Drugs</i> , 2021 , 81, 1859-1879	12.7	3
154	Patient's profiling for therapeutic management of inflammatory bowel disease: a tailored approach. <i>Expert Review of Gastroenterology and Hepatology</i> , 2020 , 14, 765-773	4.2	3
153	Biobetters in patients with immune-mediated inflammatory disorders: An international Delphi consensus. <i>Autoimmunity Reviews</i> , 2021 , 20, 102849	13.6	3
152	P036 LONG-TERM SAFETY AND EFFICACY OF THE ANTI-MUCOSAL ADDRESSIN CELL ADHESION MOLECULE-1 (MADCAM-1) ANTIBODY SHP647 IN ULCERATIVE COLITIS: AN OPEN-LABEL EXTENSION STUDY (TURANDOT II). <i>Inflammatory Bowel Diseases</i> , 2019 , 25, S18-S18	4.5	3
151	Medical therapy versus surgery in moderate-to-severe ulcerative colitis. <i>Digestive and Liver Disease</i> , 2021 , 53, 403-408	3.3	3
150	Evolution of infliximab biosimilar in inflammatory bowel disease: from intravenous to subcutaneous CT-P13. <i>Expert Opinion on Biological Therapy</i> , 2021 , 21, 37-46	5.4	3
149	Nocebo effect and biosimilars in inflammatory bowel diseases: what's new and what's next?. <i>Expert Opinion on Biological Therapy</i> , 2021 , 21, 47-55	5.4	3
148	PTG-100, an Oral μ Antagonist Peptide: Preclinical Development and Phase 1 and 2a Studies in Ulcerative Colitis. <i>Gastroenterology</i> , 2021 , 161, 1853-1864.e10	13.3	3
147	Incidence of and Risk Factors for Colorectal Strictures in Ulcerative Colitis: A Multicenter Study. <i>Clinical Gastroenterology and Hepatology</i> , 2021 , 19, 1899-1905.e1	6.9	3

146	Endoscopic vacuum therapy for post-esophagectomy anastomotic dehiscence as rescue treatment: a single center case series.. <i>Esophagus</i> , 2022 , 1	5.4	3
145	Efficacy and Safety of Oral Tofacitinib as Maintenance Therapy in Patients with Moderate to Severe Ulcerative Colitis: Results from a Phase 3 Randomized Controlled Trial. <i>Gastroenterology</i> , 2017 , 152, S199	13.3	2
144	Is Mesalamine Effective for the Induction of Remission in Crohn's Disease?. <i>Inflammatory Bowel Diseases</i> , 2017 , 23, E22-E23	4.5	2
143	DOP50 Effect of upadacitinib on extra-intestinal manifestations in patients with moderate to severe Crohn's disease: data from the CELEST study. <i>Journal of Crohn's and Colitis</i> , 2019 , 13, S057-S057	1.5	2
142	DOP51 Biomarker and pharmacokinetic data from the TURANDOT II open-label extension study of the anti-mucosal addressin cell adhesion molecule-1 (MAdCAM-1) antibody SHP647 in patients with ulcerative colitis. <i>Journal of Crohn's and Colitis</i> , 2019 , 13, S058-S059	1.5	2
141	Vedolizumab for the treatment of inflammatory bowel diseases: from symptomatic control to mucosal healing. <i>Immunotherapy</i> , 2019 , 11, 565-575	3.8	2
140	JAK selectivity: more precision less troubles. <i>Expert Review of Gastroenterology and Hepatology</i> , 2020 , 14, 789-796	4.2	2
139	PK, PD, and interactions: the new scenario with JAK inhibitors and S1P receptor modulators, two classes of small molecule drugs, in IBD. <i>Expert Review of Gastroenterology and Hepatology</i> , 2020 , 14, 797-806	4.2	2
138	Which MRI Score and Technique Should Be Used for Assessing Crohn's Disease Activity?. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	2
137	Venous Thromboembolism in Patients with Inflammatory Bowel Disease: The Role of Pharmacological Therapy and Surgery. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	2
136	JAK or GUT Selectivity: Tipping the Balance for Efficacy and Safety in Ulcerative Colitis. <i>Journal of Crohn's and Colitis</i> , 2020 , 14, 1185-1187	1.5	2
135	Telehealth in Inflammatory Bowel Disease: Every Patient May Need a Coach!. <i>Gastroenterology</i> , 2018 , 154, 1196-1198	13.3	2
134	Biologic Therapies in Ulcerative Colitis: Primi Inter Pares?. <i>Current Drug Targets</i> , 2018 , 19, 748-756	3	2
133	Safety of vedolizumab in liver transplant recipients: A systematic review. <i>United European Gastroenterology Journal</i> , 2019 , 7, 875-880	5.3	2
132	P511 Does the location of an IBD centre impact the rates of early postoperative endoscopic recurrence after ileocecal resection in Crohn's disease? Results from the MULTIPER database. <i>Journal of Crohn's and Colitis</i> , 2014 , 8, S281	1.5	2
131	Value of cross-sectional imaging in assessing active Crohn's disease before stoma reversal. <i>Digestive and Liver Disease</i> , 2017 , 49, 864-871	3.3	2
130	A Prolonged Follow-Up on the Efficacy and Safety of Infliximab Biosimilar CT-P13 in IBD Across Italy: The Prosit Cohort. <i>Gastroenterology</i> , 2017 , 152, S108	13.3	2
129	Reduced cortical thickness in patients with acute-on-chronic liver failure due to non-alcoholic etiology. <i>Journal of Translational Medicine</i> , 2015 , 13, 322	8.5	2

128	Predicting future disease course in Crohn's disease by colonoscopy or magnetic resonance: which is the crystal ball?. <i>Gut</i> , 2015 , 64, 1347-8	19.2	2
127	OP24 Clinical efficacy and safety of guselkumab maintenance therapy in patients with moderately to severely active Crohn's Disease: Week 48 analyses from the phase 2 GALAXI 1 study. <i>Journal of Crohn's and Colitis</i> , 2022 , 16, i026-i027	1.5	2
126	DOP41 Efficacy and safety of extended induction treatment with upadacitinib 45 mg once daily followed by maintenance upadacitinib 15 or 30 mg once daily in patients with moderately to severely active Ulcerative Colitis. <i>Journal of Crohn's and Colitis</i> , 2022 , 16, i090-i091	1.5	2
125	OP04 Vedolizumab intravenous is effective across multiple treatment targets in chronic pouchitis: Results of the randomised, double-blind, placebo-controlled EARNEST trial. <i>Journal of Crohn's and Colitis</i> , 2022 , 16, i004-i005	1.5	2
124	Onset of Efficacy of Tofacitinib for Induction Therapy in Patients with Active Ulcerative Colitis in Two Multinational, Phase 3 Clinical Trials. <i>American Journal of Gastroenterology</i> , 2016 , 111, S260-S261	0.7	2
123	832 Pharmacokinetics and Exposure-Response Relationships of Ustekinumab in Patients With Ulcerative Colitis: Results From the UNIFI Induction and Maintenance Studies. <i>American Journal of Gastroenterology</i> , 2019 , 114, S481-S482	0.7	2
122	Anti-fibrotic Drugs for Crohn's Disease: Ready for Prime Time?. <i>Current Pharmaceutical Design</i> , 2019 , 25, 47-56	3.3	2
121	'Treat to Target' in Mild to Moderate Ulcerative Colitis: Evidence to Support this Strategy. <i>Current Drug Targets</i> , 2021 , 22, 117-125	3	2
120	Worldwide post-marketing safety surveillance experience with tofacitinib in ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2021 ,	6.1	2
119	Evolving Treatment Algorithms in Crohn's Disease. <i>Current Drug Targets</i> , 2018 , 19, 782-790	3	2
118	Is It Crohn's Disease?. <i>Gastroenterology</i> , 2020 , 159, 1244-1246	13.3	2
117	Efficacy and Safety of Ustekinumab as Maintenance Therapy in Ulcerative Colitis: Week 44 Results from UNIFI 2019 , 57,		2
116	P565 Efficacy and safety of long-term treatment with ustekinumab in moderate-to-severe ulcerative colitis patients with delayed response to ustekinumab induction: Results from UNIFI 2-year long-term extension. <i>Journal of Crohn's and Colitis</i> , 2020 , 14, S476-S477	1.5	2
115	Evolving primary and secondary endpoints in randomized controlled trials leading to approval of biologics and small molecules in IBD: an historical perspective. <i>Expert Opinion on Biological Therapy</i> , 2020 , 20, 151-161	5.4	2
114	Histologic Features of Colon Biopsies (Geboes Score) Associated With Progression of Ulcerative Colitis for the First 36 Months After Biopsy. <i>Clinical Gastroenterology and Hepatology</i> , 2021 , 19, 2567-2576.e9	6.9	2
113	Ustekinumab for treating ulcerative colitis: an expert opinion. <i>Expert Opinion on Biological Therapy</i> , 2020 , 20, 1321-1329	5.4	2
112	Reply. <i>Clinical Gastroenterology and Hepatology</i> , 2020 , 18, 3057-3058	6.9	2
111	Tools for fecal incontinence assessment: lessons for inflammatory bowel disease trials based on a systematic review. <i>United European Gastroenterology Journal</i> , 2020 , 8, 886-922	5.3	2

110	Absence of COVID-19 Infection in Patients Accessing IBD Unit at Humanitas, Milan: Implications for Postlockdown Measures. <i>American Journal of Gastroenterology</i> , 2020 , 115, 1719-1721	0.7	2
109	Predictive Value of Bowel Ultrasound in Crohn's Disease: A 12-Month Prospective Study. <i>Clinical Gastroenterology and Hepatology</i> , 2021 ,	6.9	2
108	Histological Disease Activity Measured by the Nancy Index Is Associated with Long-term Outcomes in Patients with Ulcerative Colitis. <i>Journal of Crohn's and Colitis</i> , 2021 , 15, 1631-1640	1.5	2
107	Kidney function monitoring to prevent 5-aminosalicylic acid nephrotoxicity: What the gastroenterologist should know. <i>Digestive and Liver Disease</i> , 2021 , 53, 691-696	3.3	2
106	Defining difficult-to-treat inflammatory bowel disease: why and how. <i>The Lancet Gastroenterology and Hepatology</i> , 2021 , 6, 520-522	18.8	2
105	Time to include patients with ulcerative proctitis in clinical trials. <i>The Lancet Gastroenterology and Hepatology</i> , 2019 , 4, 900-902	18.8	2
104	Balancing Risks and Benefits in Inflammatory Bowel Disease Patients during the COVID-19 Pandemic. <i>Gastroenterology</i> , 2021 , 160, 472-473	13.3	2
103	Viral infections in inflammatory bowel disease: Tips and tricks for correct management. <i>World Journal of Gastroenterology</i> , 2021 , 27, 4276-4297	5.6	2
102	Histologic Outcomes With Vedolizumab Versus Adalimumab in Ulcerative Colitis: Results From An Efficacy and Safety Study of Vedolizumab Intravenous Compared to Adalimumab Subcutaneous in Participants With Ulcerative Colitis (VARSITY). <i>Gastroenterology</i> , 2021 , 161, 1156-1167.e3	13.3	2
101	Higher vs Standard Adalimumab Induction and Maintenance Dosing Regimens for Treatment of Ulcerative Colitis: SERENE UC Trial Results.. <i>Gastroenterology</i> , 2022 ,	13.3	2
100	DOP47 Sustained remission in patients with moderate to severe ulcerative colitis: Results from the Phase 3 UNIFI maintenance study. <i>Journal of Crohn's and Colitis</i> , 2019 , 13, S054-S055	1.5	1
99	P312 Efficacy in biologic failure and non-biologic-failure populations in a Phase 3 study of ustekinumab in moderate to severe ulcerative colitis: UNIFI. <i>Journal of Crohn's and Colitis</i> , 2019 , 13, S256-S257	1.5	1
98	Effectiveness of Infliximab Biosimilar in Crohn's Disease: A Dime, A Dozen. <i>Gastroenterology</i> , 2019 , 156, 2349-2351	13.3	1
97	P681 Ustekinumab therapy induced clinically meaningful improvement and remission as measured by the Inflammatory Bowel Disease Questionnaire: Results from the phase 3 UNIFI induction and maintenance studies. <i>Journal of Crohn's and Colitis</i> , 2019 , 13, S460-S460	1.5	1
96	OP33 BUB1: a new player in the development of Crohn's disease (CD)-associated fibrosis. <i>Journal of Crohn's and Colitis</i> , 2019 , 13, S612-S612	1.5	1
95	Author response to: Covid-19-related pancreatic injury. <i>British Journal of Surgery</i> , 2020 , 107, e191	5.3	1
94	Letter: corticosteroid use alongside tofacitinib in OCTAVE Open. Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2020 , 51, 997-998	6.1	1
93	Improving quality of care in endoscopy of inflammatory bowel disease: can we do better?. <i>Expert Review of Gastroenterology and Hepatology</i> , 2020 , 14, 819-828	4.2	1

92	DOP12 Efficacy of ustekinumab for ulcerative colitis through 2 years: Results of the UNIFI maintenance study and long-term extension. <i>Journal of Crohn's and Colitis</i> , 2020 , 14, S049-S049	1.5	1
91	P448 Dose adjustment in patients with moderate-to-severe ulcerative colitis: results from the UNIFI maintenance study long-term extension. <i>Journal of Crohn's and Colitis</i> , 2020 , 14, S403-S403	1.5	1
90	The Crohn's Disease-Ulcerative Colitis Clinical Appraisal. <i>Clinical Gastroenterology and Hepatology</i> , 2016 , 14, 638-9	6.9	1
89	P258 Abdominal pain and its relationship with clinical outcomes, biomarker levels, and health-related quality of life in patients with moderate to severe ulcerative colitis: data from U-ACHIEVE, a Phase 2b study of upadacitinib. <i>Journal of Crohn's and Colitis</i> , 2019 , 13, S226-S226	1.5	1
88	P311 Pharmacokinetics and exposure-response relationships of intravenously administered ustekinumab during induction treatment in patients with ulcerative colitis: Results from the UNIFI induction study. <i>Journal of Crohn's and Colitis</i> , 2019 , 13, S255-S256	1.5	1
87	Commentary: associations between immune activation, intestinal permeability and irritable bowel syndrome. <i>Alimentary Pharmacology and Therapeutics</i> , 2013 , 37, 277-8	6.1	1
86	Commentary: Adjunct antibiotic combination therapy for ulcerative colitis--is it time to investigate <i>Fusobacterium varium</i> ?. <i>Alimentary Pharmacology and Therapeutics</i> , 2014 , 39, 1333	6.1	1
85	Commentary: antibodies reacting with the infliximab Fab portion--something new?. <i>Alimentary Pharmacology and Therapeutics</i> , 2013 , 38, 552	6.1	1
84	P377 Impact of moderate-to-severe endoscopic disease criteria on endoscopic response, endoscopic remission, and deep remission in patients receiving ustekinumab or adalimumab in the SEAVUE study. <i>Journal of Crohn's and Colitis</i> , 2022 , 16, i379-i380	1.5	1
83	P495 Perianal fistula closure in patients receiving ustekinumab: Results from the SEAVUE and STARDUST trials. <i>Journal of Crohn's and Colitis</i> , 2022 , 16, i460-i460	1.5	1
82	Perspectives on Subcutaneous Infliximab for Rheumatic Diseases and Inflammatory Bowel Disease: Before, During, and After the COVID-19 Era.. <i>Advances in Therapy</i> , 2022 , 1	4.1	1
81	P230 Ultrasonography-based and Magnetic Resonance-based Lhann Index: two sides of the same coin. <i>Journal of Crohn's and Colitis</i> , 2022 , 16, i278-i279	1.5	1
80	OP15 A new simplified histology artificial intelligence system for accurate assessment of remission in Ulcerative Colitis. <i>Journal of Crohn's and Colitis</i> , 2022 , 16, i015-i017	1.5	1
79	S0653 Long-Term Treatment With Vedolizumab SC in Ulcerative Colitis: Interim Results From VISIBLE OLE. <i>American Journal of Gastroenterology</i> , 2020 , 115, S327-S327	0.7	1
78	Thiopurines and non-melanoma skin cancer: partners in crime in inflammatory bowel diseases. <i>British Medical Bulletin</i> , 2020 , 136, 107-117	5.4	1
77	Diversion proctocolitis and the problem of the forgotten rectum in inflammatory bowel diseases: A systematic review. <i>United European Gastroenterology Journal</i> , 2021 , 9, 1157	5.3	1
76	Magnetic Resonance Elastography for Assessing Fibrosis in Patients with Crohn's Disease: A Pilot Study. <i>Digestive Diseases and Sciences</i> , 2021 , 1	4	1
75	Therapeutic Drug Monitoring of Biologics in IBD: Essentials for the Surgical Patient. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	1

74	Anti-adhesion Molecules in IBD: Does Gut Selectivity Really Make the Difference?. <i>Current Pharmaceutical Design</i> , 2019 , 25, 19-24	3.3	1
73	Iron deficiency: the hidden miscreant in inflammatory bowel disease. <i>Current Drug Targets</i> , 2014 , 15, 1011-9	3	1
72	Prevention of Postoperative Recurrence in CD: Tailoring Treatment to Patient Profile. <i>Current Drug Targets</i> , 2019 , 20, 1327-1338	3	1
71	Thrombosis in IBD in the Era of JAK Inhibition. <i>Current Drug Targets</i> , 2021 , 22, 126-136	3	1
70	Protecting patients with IBD during the COVID-19 pandemic. <i>The Lancet Gastroenterology and Hepatology</i> , 2020 , 5, 639	18.8	1
69	Comparison of two methods for the in-vivo diagnosis of Helicobacter pylori infection using a tablet of 13C-urea. <i>Minerva Gastroenterology</i> , 2017 , 63, 319-326	3	1
68	Phase I, II and III Trials in Inflammatory Bowel Diseases: A Practical Guide for the Non-specialist. <i>Journal of Crohn's and Colitis</i> , 2020 , 14, 710-718	1.5	1
67	Reply. <i>Clinical Gastroenterology and Hepatology</i> , 2020 , 18, 3055	6.9	1
66	Predictors for short bowel syndrome in Crohn's disease. <i>Digestive and Liver Disease</i> , 2020 , 52, 1455-1460	3.3	1
65	Endoscopy after surgery in inflammatory bowel disease: Crohn's disease recurrence and pouch surveillance. <i>Expert Review of Gastroenterology and Hepatology</i> , 2020 , 14, 829-841	4.2	1
64	P376 Effects of IV vedolizumab on health-related quality of life and work productivity in patients with Crohn's disease: results from the Phase 3b VERSIFY trial. <i>Journal of Crohn's and Colitis</i> , 2019 , 13, S293-S294	1.5	1
63	634 Transitioning From Vedolizumab IV to Vedolizumab SC in Patients With Ulcerative Colitis: Results From the VISIBLE Program. <i>American Journal of Gastroenterology</i> , 2019 , 114, S369-S370	0.7	1
62	215 Efficacy and Safety of Upadacitinib as an Induction Therapy for Patients With Moderately-to-Severely Active Ulcerative Colitis: Combined Results From 382 Subjects in the Phase 2b Study U-ACHIEVE. <i>American Journal of Gastroenterology</i> , 2019 , 114, S131-S131	0.7	1
61	772 Long-Term Mucosal Healing, Clinical Response and Clinical Remission in Patients With Ulcerative Colitis Treated With the Anti-MAdCAM-1 Antibody Ontamalimab: Results From the Open-Label Extension Study TURANDOT II. <i>American Journal of Gastroenterology</i> , 2019 , 114, S448-S449	0.7	1
60	Clinical, Endoscopic and Histological Outcomes in Induction of Moderate-to-Severe Ulcerative Colitis: A Systematic Review with Meta-Analysis. <i>Journal of Crohn's and Colitis</i> , 2021 , 15, 551-566	1.5	1
59	Authors' Reply to Pires et al.: "Switching Reference Medicines to Biosimilars: A Systematic Literature Review of Clinical Outcomes". <i>Drugs</i> , 2018 , 78, 853-855	12.1	1
58	Meta-Analysis of the Association Between Anti-Tumour Necrosis Factor Use and Lymphoma Risk in Patients With Inflammatory Bowel Disease: Methodological Considerations. <i>Journal of Crohn's and Colitis</i> , 2018 , 12, 1257-1258	1.5	1
57	Challenges and Opportunities in IBD Clinical Trial Design. <i>Gastroenterology</i> , 2021 , 161, 400-404	13.3	1

56	Anti-integrin drugs in clinical trials for inflammatory bowel disease (IBD): insights into promising agents. <i>Expert Opinion on Investigational Drugs</i> , 2021 , 30, 1037-1046	5.9	1
55	Rediscovering histology: what is new in endoscopy for inflammatory bowel disease?. <i>Therapeutic Advances in Gastroenterology</i> , 2021 , 14, 17562848211005692	4.7	1
54	Difficult-to-treat inflammatory bowel disease: results from a global IOIBD survey.. <i>The Lancet Gastroenterology and Hepatology</i> , 2022 , 7, 390-391	18.8	1
53	Going Beyond Bacteria: Uncovering the Role of Archaeome and Mycobiome in Inflammatory Bowel Disease.. <i>Frontiers in Physiology</i> , 2021 , 12, 783295	4.6	1
52	Is it time to include older adults in inflammatory bowel disease trials? A call for action. <i>The Lancet Healthy Longevity</i> , 2022 , 3, e356-e366	9.5	1
51	Psychological Functioning of Patients With Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2019 , 25, e112	4.5	0
50	Leukoapheresis in Crohn's disease: the final curtain?. <i>Gut</i> , 2013 , 62, 487-8	19.2	0
49	OP07 Exploring disease control by combining clinical, biological, and health-related quality of life remission with endoscopic improvements among Ulcerative Colitis patients treated with filgotinib: A post-hoc analysis from the SELECTION trial. <i>Journal of Crohn's and Colitis</i> , 2022 , 16, i007-i008	1.5	0
48	DOP80 Integrated tissue transcriptomic and serum proteomic interrogation reveals biomarkers for endoscopic improvement and histologic remission after JAK3/TEC inhibition in Ulcerative Colitis (UC) (Phase 2b Vibrato study). <i>Journal of Crohn's and Colitis</i> , 2022 , 16, i124-i124	1.5	0
47	DOP37 Efficacy and safety of filgotinib in patients with Ulcerative Colitis stratified by age: Post hoc analysis of the phase 2b/3 SELECTION and SELECTIONLTE studies. <i>Journal of Crohn's and Colitis</i> , 2022 , 16, i085-i087	1.5	0
46	OP19 Classifying perianal fistulising Crohn's Disease: An expert-consensus to guide decision-making in daily practice and clinical trials. <i>Journal of Crohn's and Colitis</i> , 2022 , 16, i021-i022	1.5	0
45	Promoting psycho-social wellbeing for engaging inflammatory bowel disease patients in their care: an Italian consensus statement. <i>BMC Psychology</i> , 2021 , 9, 186	2.8	0
44	Randomised clinical trial: a phase 1b study of GB004, an oral HIF-1 β stabiliser, for treatment of ulcerative colitis.. <i>Alimentary Pharmacology and Therapeutics</i> , 2022 , 55, 401	6.1	0
43	Efficacy of a New Nutraceutical Formulation in Patients with Symptomatic Uncomplicated Diverticular Disease (SUDD): a Prospective Observational Study. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2019 , 28, 49-52	1.4	0
42	A Treat to Target Approach Decreases the Rate of CD-Related Adverse Outcomes versus a Clinical Approach in Patients With Moderate to Severely Active Crohn's Disease: Data From CALM 2017 ACG Governors Award for Excellence in Clinical Research. <i>American Journal of Gastroenterology</i> , 2017 , 112, S321	0.7	0
41	Ethnic Differences in the Smoking-related Risk of Inflammatory Bowel Disease: A Systematic Review and Meta-analysis. <i>Journal of Crohn's and Colitis</i> , 2021 , 15, 1658-1678	1.5	0
40	P383 Relationship between histo-endoscopic mucosal healing and baseline characteristics in patients with moderately to severely active Ulcerative Colitis receiving filgotinib in the phase 2b/3 SELECTION study. <i>Journal of Crohn's and Colitis</i> , 2021 , 15, S395-S396	1.5	0
39	IBD goes home: from telemedicine to self-administered advanced therapies. <i>Expert Opinion on Biological Therapy</i> , 2021 , 1-13	5.4	0

38	Systematic Review and Principal Components Analysis of the Immunogenicity of Adalimumab. <i>BioDrugs</i> , 2021 , 35, 35-45	7.9	o
37	An Unusual Case of Cardiac Involvement in Crohn's Disease. <i>Gastroenterology</i> , 2021 , 161, 431-433	13.3	o
36	Confounding and bias in observational studies in inflammatory bowel disease: a meta-epidemiological study. <i>Alimentary Pharmacology and Therapeutics</i> , 2021 , 53, 712-721	6.1	o
35	The Role of the Multidisciplinary Health Care Team in the Management of Patients with Systemic Sclerosis.. <i>Journal of Multidisciplinary Healthcare</i> , 2022 , 15, 815-824	2.8	o
34	High prevalence of SARS-Coronavirus-2 in patients with inflammatory bowel disease and the role of soluble angiotensin converting Enzyme2. <i>Archives of Physiology and Biochemistry</i> , 1-8	2.2	o
33	P477 Clinical remission by legacy vs. FDA definitions: definition justification and results from UNIFI Study. <i>Journal of Crohn's and Colitis</i> , 2019 , 13, S350-S351	1.5	
32	P029 Serum bile acids profiling in IBD patients treated with anti-TNFs. <i>Journal of Crohn's and Colitis</i> , 2019 , 13, S100-S101	1.5	
31	P499 Efficacy and safety of 2 or 3 vedolizumab intravenous infusions as induction therapy for ulcerative colitis and Crohn's disease: results from VISIBLE 1 and 2. <i>Journal of Crohn's and Colitis</i> , 2019 , 13, S361-S362	1.5	
30	Letter: thromboembolic and cardiovascular events with tofacitinib in ulcerative colitis-two cases in real world clinical practice. Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2020 , 51, 1209-1210	6.1	
29	Reply. <i>Gastroenterology</i> , 2020 , 158, 1177-1178	13.3	
28	P406 General health status in patients with moderate to severe ulcerative colitis receiving ustekinumab: results from the Phase 3 UNIFI induction and maintenance studies. <i>Journal of Crohn's and Colitis</i> , 2019 , 13, S311-S312	1.5	
27	Assessment of anti-prothrombin antibodies in thrombosis complicating inflammatory bowel diseases. <i>International Journal of Colorectal Disease</i> , 2013 , 28, 1281-6	3	
26	P004 Stimulation of CYP450-mediated ω 6 docosahexaenoic acid metabolism via MFSD2A as a novel therapy for inflammatory bowel disease. <i>Journal of Crohn's and Colitis</i> , 2017 , 11, S81-S81	1.5	
25	DOP90 Efficacy of the treat-to-target approach in modifying disease course with ustekinumab in patients with moderate-to-severe Crohn's Disease: Results from the STARDUST trial. <i>Journal of Crohn's and Colitis</i> , 2022 , 16, i132-i134	1.5	
24	Surgery versus Medical Therapy in Luminal Ileocecal Crohn's Disease.. <i>Clinics in Colon and Rectal Surgery</i> , 2022 , 35, 72-77	2.3	
23	P457 Long-term cumulative safety of ustekinumab in bionative patients with Crohn's Disease and Ulcerative Colitis. <i>Journal of Crohn's and Colitis</i> , 2022 , 16, i434-i435	1.5	
22	P267 Milan Ultrasound Criteria are accurate in assessing endoscopic remission and treatment response in patients with ulcerative colitis. <i>Journal of Crohn's and Colitis</i> , 2022 , 16, i306-i307	1.5	
21	817 Identification of Biomarkers and Mechanistic Insight for Upadacitinib in Crohn's Disease: Serum Inflammatory Mediator Analysis From the Phase 2b CELEST Study. <i>American Journal of Gastroenterology</i> , 2019 , 114, S471-S471	0.7	

20	Vedolizumab Results in Durable Clinical Remission in Crohn's Disease. <i>American Journal of Gastroenterology</i> , 2014 , 109, S476-S477	0.7
19	Symptomatic Improvement Within 3 Days With Tofacitinib Induction Therapy in Patients With Ulcerative Colitis: Results From OCTAVE Induction 1 and 2. <i>American Journal of Gastroenterology</i> , 2017 , 112, S331	0.7
18	New Paradigms to Help Decisions in Treatment Choice: Head to Head Trial of Biological Therapies in Inflammatory Bowel Diseases. <i>Current Drug Targets</i> , 2021 , 22, 370-378	3
17	Reply. <i>Gastroenterology</i> , 2021 , 160, 2223-2224	13.3
16	DOP84 Early treatment responses within 14 days of intravenous vedolizumab induction therapy for Crohn's Disease: Post hoc analysis of patient-reported outcomes from the VISIBLE 2 study. <i>Journal of Crohn's and Colitis</i> , 2021 , 15, S115-S116	1.5
15	Reply. <i>Clinical Gastroenterology and Hepatology</i> , 2021 ,	6.9
14	P271 Evolving Targets in Ulcerative colitis: Defining Disease Clearance in the VARSITY Study. <i>Journal of Crohn's and Colitis</i> , 2021 , 15, S305-S305	1.5
13	PTU-072 Discontinuation of Infliximab in Patients with Ulcerative Colitis is Associated with Increased Risk of Relapse: A Multinational Retrospective Cohort Study. <i>Gut</i> , 2016 , 65, A88-A89	19.2
12	715 Corticosteroid Sparing Effects of Ustekinumab Therapy in UC Patients: Results From the UNIFI Program. <i>American Journal of Gastroenterology</i> , 2019 , 114, S421-S421	0.7
11	689 Early Improvement After Intravenous Ustekinumab Induction in Patients With Ulcerative Colitis: Results From the UNIFI Induction Trial. <i>American Journal of Gastroenterology</i> , 2019 , 114, S404-S404	0.7
10	842 Impact of Response and Inflammatory Burden at Start of Maintenance Therapy on Clinical Efficacy of Ustekinumab Dosing Regimen in UC: Week 44 Results From UNIFI. <i>American Journal of Gastroenterology</i> , 2019 , 114, S487-S488	0.7
9	757 Histologic Improvement With Vedolizumab vs. Adalimumab in Ulcerative Colitis: Results From VARSITY. <i>American Journal of Gastroenterology</i> , 2019 , 114, S442-S442	0.7
8	697 Safety of Ustekinumab in Inflammatory Bowel Diseases: Integrated Safety Analysis of Results From Phase 2 and 3 Studies in Crohn's Disease and Ulcerative Colitis. <i>American Journal of Gastroenterology</i> , 2019 , 114, S408-S409	0.7
7	P380 A prospective multi-centre observational cohort study assessing the effectiveness of Budesonide MMX [®] for mild-to-moderate ulcerative colitis. <i>Journal of Crohn's and Colitis</i> , 2019 , 13, S296-S297	1.5
6	644 Incidence of Venous Thromboembolic Events in Patients With Ulcerative Colitis Treated With Tofacitinib in the Ulcerative Colitis Clinical Development Program. <i>American Journal of Gastroenterology</i> , 2019 , 114, S377-S377	0.7
5	Quality of Care in Ulcerative Colitis: A Modified Delphi Panel Approach. <i>Digestive Diseases</i> , 2018 , 36, 346-353	3.5
4	Adalimumab biosimilar in inflammatory bowel disease. <i>The Lancet Gastroenterology and Hepatology</i> , 2021 , 6, 775-776	18.8
3	JAK inhibitors in crohn's disease: ready to go?. <i>Expert Opinion on Investigational Drugs</i> , 2022 , 1-17	5.9

2	Systematic Literature Review and Meta-analysis: Real-World Mucosal Healing in Vedolizumab-Treated Patients with Crohn's Disease. <i>GastroHep</i> , 2022 , 2022, 1-12	1
1	Composite outcomes in observational studies of Crohn's disease: a systematic review and meta-analysis. <i>Therapeutic Advances in Gastroenterology</i> , 2022 , 15, 175628482210927	4-7